[ biotech news ] Schaeffer's S&P 500 Index Hot Stocks Features Brunswick, MedImmune, Merck, Delph

------------------------ Yahoo! Groups Sponsor --------------------~-->
Get fast access to your favorite Yahoo! Groups. Make Yahoo! your home page
http://us.click.yahoo.com/dpRU5A/wUILAA/yQLSAA/H4xqlB/TM
--------------------------------------------------------------------~->

Schaeffer's S&P 500 Index Hot Stocks Features Brunswick, MedImmune,
Merck, Delphi, and Murphy Oil

Aug. 29, 2005
Among the stocks featured in the August 29 edition of Schaeffer's
S&P 500 Index Hot Stocks are Brunswick (NYSE:BC), MedImmune
(NASDAQ:MEDI), Merck (NYSE:MRK), Delphi (NYSE:DPH), and Murphy Oil
(NYSE:MUR). Schaeffer's S&P 500 Index Hot Stocks is just one of the
many free market commentaries written every day at
www.SchaeffersResearch.com - the home of Bernie Schaeffer and
Schaeffer's Investment Research.

Schaeffer's S&P 500 Index Hot Stocks for Monday, August 29, 2005:

A daily feature available on SchaeffersResearch.com is the "SPX Hot
Stocks" column. Each afternoon, we will provide a list of the day's
top-20 performing stocks in the S&P 500 Index (SPX - 1,210.76) as
well as the bottom-20 names. Featured along with this table will be
news that is moving some of the securities.

NOTE: Stocks trading under $5 per share have been eliminated from
this listing of the top-20 and bottom-20 performing stocks.

Despite oil ascending to record heights in today's trading action,
the SPX has been able to advance 0.47 percent. Overnight, crude
futures hit $70.80; however, last check shows that black gold is
trading 87 cents higher on the day at $67 per barrel. The market
action seems to be defying what investors expect, with some stating
that stocks "should be trading a lot lower." Currently, we only have
short-term estimates about the damage Katrina has caused, some
investors believe that the market will suffer as the sky clears and
we can get a handle on the damage.

Atop the hot stocks list this afternoon is Allegheny Technologies
(ATI) with a gain of more than four percent on no discernable news,
and seeing how this is a news driven article, I will skip over
PerkinElmer (PKI) and move on to Brunswick (NYSE:BC). The Illinois-
based producer of all things leisure, except for those hideous
polyester suits, received an upgrade from "hold" to "buy" from the
kind-hearted analysts at Citigroup. BC produces pleasure boats,
bowling and billiard products, and fitness equipment.

Moving further down the list, I see a gain of more than two percent
for biotech equity, MedImmune (NASDAQ:MEDI). MEDI licensed the
worldwide rights from GlaxoSmithKline (GSK) to develop
antistaphylococcal monoclonal antibodies in exchange for an upfront
payment. Possible milestone fees and future royalties are also
included in the deal. MEDI has also taken over future milestone and
royalty payments to Biosynexus, from whom GSK originally licensed
the BSYX-A110 antibody, which will help the company expand into the
development of monoclonal antibodies in pediatrics.

I had to dig all the way down to the final advancer on the day to
find any kind of news to report, and it is actually good news for
shaken pharmaceutical firm Merck (NYSE: MRK). This afternoon, the
purveyor of pills to cure your ills advanced thanks mainly to
Hurricane Katrina. The first federal case filed over its recalled
drug Vioxx was set to go to trial in New Orleans in November.
Today's storm may serve to delay this case as the citizens of the
city clean up after Hurricane Katrina.

On Friday, Delphi (NYSE:DPH) led a group of auto parts makers lower,
and its decline hasn't stopped today. Tomorrow, DPH's former parent,
General Motors (GM), will discuss at its analyst meeting whether or
not it will help lend some financial relief to its struggling
supplier. This news follows a week where the dean of the driveshaft
saw itself upgraded to "neutral" from "underperform" at Baird.
Unfortunately, Friday's fall included Dana (DCN), which seems to be
tethered to DPH again today, as both equities have lost more than
four percent.

Hurricane Katrina has boosted oil and oil-related stocks, but one
oil stock that is not advancing thanks to the weather is Murphy Oil
(NYSE:MUR). Forecasters say that Katrina hit land at Plaquemines
Parish, Louisiana, which is near MUR's refinery at Meraux,
Louisiana. The Meraux facility usually pumps out 120,000 barrels of
black gold per day.

About an hour ago, AIR Worldwide estimated that Hurricane Katrina
could cost the insurance industry between $12 billion and $26
billion. If the cleanup carries that hefty of a price tag, it will
be one of the two worst natural catastrophes in U.S. history. This
news has not helped the insurance industry, proven by a drop of
nearly two percent from Allstate (ALL).

Take advantage of the timely Schaeffer commentaries by signing up
for their free e-newsletters -- Opening View, Market Recap and
Monday Morning Outlook. Click here to have the Schaeffer's
commentaries delivered to you free via email every day.

About Schaeffer's Investment Research (www.SchaeffersResearch.com)

Schaeffer's Investment Research, founded by Bernie Schaeffer in
1981, is a financial information and trading resources company. It
publishes Bernie Schaeffer's Option Advisor, the nation's leading
options subscription newsletter. The firm's contrarian approach
focuses on stocks with technical and fundamental trends that run
counter to investor expectations.

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/
http://www.arizonabiotech.com/index.php

http://www.arizonabiotech.com/
<a href="http://www.arizonabiotech.com/">Arizona Biotech</a>
http://groups.yahoo.com/group/biotech-news/
<a href="http://groups.yahoo.com/group/biotech-news/">Biotech News</a>
http://www.arizonaentrepreneurs.com/
<a href="http://www.arizonaentrepreneurs.com/">Arizona Entrepreneurs</a>
http://www.azhttp.com/
<a href="http://www.azhttp.com/">Arizona High Tech</a>

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] Novel lipoplex nanoparticle to be used in 1st human trial treating advanced soli

------------------------ Yahoo! Groups Sponsor --------------------~-->
Get fast access to your favorite Yahoo! Groups. Make Yahoo! your home page
http://us.click.yahoo.com/dpRU5A/wUILAA/yQLSAA/H4xqlB/TM
--------------------------------------------------------------------~->

Novel lipoplex nanoparticle to be used in 1st human trial treating
advanced solid cancer

The first clinical trial of a biologic nanoparticle designed to give
back to cancer patients the tumor-busting gene they have lost is
expected to start in September at Georgetown University Medical
Center.

e phase I clinical study will enroll 20 patients with advanced solid
cancers ( including most common tumor types ), and is the
culmination of more than a decade of work by a team of researchers
led by Professor Esther H. Chang, Ph.D. at the Lombardi
Comprehensive Cancer Center.

Their research has led to development of a tiny structure --
measuring a millionth of an inch across -- that resembles a virus
particle that can penetrate deeply into the tumor and move
efficiently into cells. The device is a "liposome" -- a microscopic
globule made of lipids -- that is spiked on the outside with
antibody molecules that will seek out, bind to, and then enter
cancer cells including metastases wherever they hide in the body.
These molecules bind to the receptor for transferrin that is present
in high numbers on cancer cells.

Once inside, the nanoparticle, which the researchers call
a "immunolipoplex," will deliver its payload -- the p53 gene whose
protein helps to signal cells to self-destruct when they have the
kind of genetic damage characterized by cancer and by cancer
therapies.

More than half of all cancer patients have cancer cells that have
lost normal functioning of the p53 gene, so-called "guardian of the
genome," and the Georgetown researchers believe that restoring the
gene will improve the tumor-killing ability of traditional
treatments.

"We are excited about the promise this nanoparticle has shown in
animal tumor models, and are anxious to offer it to patients," said
Chang, Professor in the Department of Oncology and Co-director of
the Molecular Targets & Developmental Therapeutics Program at
Georgetown.

The federal Food and Drug Administration granted approval for the
trial to begin in late July. The work is being sponsored by grants
from the National Institutes of Health and private foundations.
Additional support comes from SynerGene Therapeutics, a biotech
research firm with which Chang collaborates.

John Marshall, M.D., Director of Developmental Therapeutics and GI
Oncology at Georgetown, will serve as the trial's principal
investigator.

The researchers believe that immunolipoplex represents an advance
over the viral "vectors" that have been used to deliver gene
therapy, because these liposomes do not produce the kinds of
immunologic response seen when disabled viruses are used to carry
the payload. They also say that the nanoparticle is of a small
uniform size and consistency, and has been proven to work in animals
bearing tumor.

In preclinical research, Chang and long-term research colleague
Kathleen Pirollo, Ph.D. have found that these nanoparticles
substantially improve the tumor-fighting power of both chemotherapy
and radiation therapy. These agents work synergistically with
traditional therapies because the newly restored p53 protein helps
push cancer cells that are now damaged to self-destruct.

"We believe this approach will make it difficult for the cancer
cells to become resistant to therapy," Chang said. "As a result,
cancers treated with these liposomal formulations should be less
likely to recur after therapy is complete."

For example, use of these p53-loaded liposomes in combination with
radiation therapy eliminated prostate and head and neck tumors in
mice, which then survived cancer-free for more than 200 days --
until they all died of old age. Similar promising results were seen
when the nanoparticles were combined with chemotherapy to treat
animal models of melanoma and aggressive breast cancer.

Among the solid tumors approved for testing in the clinical trial
are head and neck, prostate, pancreatic, breast, bladder, colon,
cervical, brain, melanoma, liver and lung cancers.

Laura Cavender
lsc6 @ georgetown.edu
202-687-5100
Georgetown University Medical Center
gumc.georgetown.edu

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/
http://www.arizonabiotech.com/index.php

http://www.arizonabiotech.com/
<a href="http://www.arizonabiotech.com/">Arizona Biotech</a>
http://groups.yahoo.com/group/biotech-news/
<a href="http://groups.yahoo.com/group/biotech-news/">Biotech News</a>
http://www.arizonaentrepreneurs.com/
<a href="http://www.arizonaentrepreneurs.com/">Arizona Entrepreneurs</a>
http://www.azhttp.com/
<a href="http://www.azhttp.com/">Arizona High Tech</a>

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] SciFinder 2006 launches powerful new substance search capablities

------------------------ Yahoo! Groups Sponsor --------------------~-->
Get fast access to your favorite Yahoo! Groups. Make Yahoo! your home page
http://us.click.yahoo.com/dpRU5A/wUILAA/yQLSAA/H4xqlB/TM
--------------------------------------------------------------------~->

SciFinder 2006 launches powerful new substance search capablities

Washington, D.C., August 28, 2005 - Building upon a decade of
innovation, the new SciFinder 2006 advances its reputation as an
essential information tool and part of the process of chemical and
pharmaceutical research. For the first time, scientists exploring
the CAS Registry of 26 million organic and inorganic chemical
substances can retrieve "similar substances" to foster new ideas and
directions in drug discovery and other fields of scientific
inquiry. "Similarity Searching" is only one of several new features
adding new power and depth to SciFinder this year. CAS, a division
of the American Chemical Society, launched SciFinder 2006 and
SciFinder Scholar 2006 this week at the American Chemical Society
meeting in Washington, D.C.

SciFinder provides similarity searching of CAS registry
Washington, D.C., August 28, 2005 - Building upon a decade of
innovation, the new SciFinder 2006 advances its reputation as an
essential information tool and part of the process of chemical and
pharmaceutical research. For the first time, scientists exploring
the CAS Registry of 26 million organic and inorganic chemical
substances can retrieve "similar substances" to foster new ideas and
directions in drug discovery and other fields of scientific
inquiry. "Similarity Searching" is only one of several new features
adding new power and depth to SciFinder this year. CAS, a division
of the American Chemical Society, launched SciFinder 2006 and
SciFinder Scholar 2006 this week at the American Chemical Society
meeting in Washington, D.C.
Nobel Laureate, Dr. K. Barry Sharpless, W. M. Keck Professor of
Chemistry at the Scripps Research Institute, shared his reflections
regarding the significance of SciFinder:

"We were using SciFinder at Scripps even before SciFinder Scholar
was invented," said Dr. Sharpless. "I am a big user and don't see
how any researcher could hope to excel without daily, round-the-
clock access. In the old days, you could be forgiven for not knowing
about a certain paper, but now there is no excuse. The speed and
scope of its search power is amazing, and the answer to 'what aspect
is most helpful for you?' could be as diverse as the users. In my
case, SciFinder enhances my reactivity insights, making it easier
to 'see' those ill-defined boundaries where important new phenomena
are lurking."

New features of SciFinder 2006 include:

Similarity Searching - as a complement to SciFinder substructure
searching, similarity searching permits new options for identifying
substances of interest via precise statistical analysis using the
Tanimoto algorithm;

Structure Query Tools - to identify substances more precisely, new
tools permit drawing a variable attachment point and a repeating
group;

Reaction Searching - finding reaction information has been enriched
with new content and features; these include reaction conditions and
identifying intermediate reactions in a multi-step reaction.
Scientists can also click any substance in the reaction display to
find additional information, including retro-synthetic pathways;

Navigation & Usability - improvements include duplicate detection
and removal for more efficient combined searching of the CAplus and
MEDLINE databases. A new Locate feature permits quick access to
journal and patent documents by entering journal titles, author
names and other partial bibliographic information.
While announcing the release of SciFinder 2006 for Windows, CAS
revealed that a native MAC OS X version of SciFinder will appear in
fourth quarter 2005.

SciFinder was created in 1995 with the vision of providing
scientists easy, point-and-click access to chemical information. The
new intelligent research tool -- a client-server product for the
desktop -- was an immediate hit with scientists, assisting them and
other researchers worldwide with access to the multidisciplinary CAS
databases. Today, tens of thousands of scientists at pharmaceutical,
biotech and chemical companies around the world use SciFinder
regularly to explore research topics, browse scientific journals and
stay up-to-date on recent scientific developments. SciFinder Scholar
was introduced in 1998 to serve the needs of campus-wide searching
in academia and now serves more than 1,000 institutions of higher
learning worldwide.

###
CAS, a division of the American Chemical Society, provides the
world's largest and most current collection of chemical and related
scientific information, including the most authoritative database of
chemical substances, the CAS Registry. CAS combines these databases
with advanced search and analysis technologies to deliver the most
complete and effective digital information environment for
scientific research and discovery, including such products as
SciFinder, SciFinder Scholar, STN, STN Express and STN AnaVist,
among others. The CAS web site is at www.cas.org.

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/
http://www.arizonabiotech.com/index.php

http://www.arizonabiotech.com/
<a href="http://www.arizonabiotech.com/">Arizona Biotech</a>
http://groups.yahoo.com/group/biotech-news/
<a href="http://groups.yahoo.com/group/biotech-news/">Biotech News</a>
http://www.arizonaentrepreneurs.com/
<a href="http://www.arizonaentrepreneurs.com/">Arizona Entrepreneurs</a>
http://www.azhttp.com/
<a href="http://www.azhttp.com/">Arizona High Tech</a>

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
Biotech research center wins $1 million in grants - 2005-08-29
Biotech research center wins $1 million in grants - 2005-08-29

Biotech research center wins $1 million in grants
NMBW Staff
The National Center for Genome Resources (NCGR) announced Monday it has received two grants worth more than $1 million to develop information and search systems for agricultural researchers.


The two grants were both awarded by the Agricultural Research Service, a division of the U.S. Department of Agriculture.

The first grant, totaling $790,000, will be used by the Santa Fe-based NCGR for the continued development of the four-year-old Legume Information System (LIS). LIS is a Web-based information tool that has been used by scientists nationwide to translate model plant species to economically feasible crops, according to the NCGR announcement.

NCGR will continue to work with the Agricultural Research Service on the LIS project.

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
Business 2.0 :: Magazine Article :: Features :: Tech Giants Court The Genome Crowd
Tech Giants Court The Genome Crowd

Desperate for good news and new markets, leading technology companies look toward red-hot genomics and bioinformatics for salvation.

Business 2.0 :: Magazine Article :: Features :: Tech Giants Court The Genome Crowd



By Carolyn Marshall, May 29, 2001

It's close to midnight in San Francisco and J. Craig Venter, president and chief scientific officer of Celera Genomics, is dancing like a madman. Black tie still tight, Venter mock surfs in rhythm to a blaring oldie by the Beach Boys. The maverick scientist, it seems, is the beau of this $85,000 ball, the first of several champagne-and-caviar events planned worldwide and hosted by Celera's gene team to honor the men and women who made DNA a household word.


Venter is both blamed and credited with triggering a bitter rivalry between the public and private teams racing to decode the Human Genome. The teams delivered final versions of the gene map in February and since then it has been non-stop for Venter and his colleagues: press conferences, seminars, television appearances and, yes, time spent with gene groupies and Nobel wannabes anxious to snag an autograph or pose with Venter for a snapshot.


But behind every larger-than-life celebrity, a phalanx of assistants exist-rarely seen but essential to maintaining the star's celebrity status. In this case, that phalanx is a $50 million supercomputing "server farm" with 600 DNA sequencing machines and 64-bit, 833 MHz AlphaServer systems made by Compaq Computer.


"Celera never would have been able to pull this off without us," crows Ty Rabe, Compaq's director of High Performance Technical Computing Solutions, in Marlboro, Mass.



Biotech News
Biotech News
AZ Entrepreneurs
AZ Tech
Biotechnology News Forums
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
Largest Scientific Conference of Year To-Date on Anti-Aging Medicine Explores Major Breakthroughs in Human Longevity
Largest Scientific Conference of Year To-Date on Anti-Aging Medicine Explores Major Breakthroughs in Human Longevity
American Academy of Anti-Aging Medicine (A4M) welcomes 3,000-plus physicians and scientists to Chicago, as more than 3,000 delegates participated in the world's largest scientific conference to-date on the topics of medical intervention to prevent and treat the diseases and disabilities associated with the biological process of aging.


More than 3,000 delegates participated in the world's largest scientific conference to-date on the topics of medical intervention to prevent and treat the diseases and disabilities associated with the biological process of aging.

These cutting-edge innovative physicians and health practitioners who are involved in improving and extending the human lifespan represented more than 50 nations around the world.

Taking place from Aug. 18-21, the XIII Annual International Congress on Anti-Aging Medicine Summer 2005 Session offered 50 hours of Category 1 AMA/PRA Credits focusing on scientific educational programming in some of the most promising arenas of preventive medicine, including:
- Stem cell therapeutics and regenerative medicine
- Laser surgery, skin resurfacing, fillers, and other facets of aesthetic medicine
- Biomarkers of aging
- Obesity and medical weight management
- Cardiovascular disease prevention and treatment
- Hormone replacement therapy
- Vitamin therapies
- Cognitive testing and maintenance of mental performance

Comments Dr. Ronald Klatz, A4M founder and President: "The faculty of this event consisted of dozens of high-caliber, world-renowned specialists in their respective scientific fields. The level of academic programming at the XIII International Congress on Anti-Aging Medicine remains unparalleled when compared to any other scientific conferences in preventive medicine and/or biotech around the world."

The XIII Annual International Congress on Anti-Aging Medicine's Summer 2005 Session was sponsored by The American Academy of Anti-Aging Medicine (A4M; http://www.worldhealth.net), the academic leader in a worldwide movement in life enhancement and life extension that involves more than 50,000 physicians in 80 countries. The A4M is a non-profit medical society dedicated to the advancement of technology to detect, prevent, and treat aging related disease and to promote research into methods to retard and optimize the human aging process. A4M is also dedicated to educating physicians, scientists, and members of the public on biomedical sciences, breaking technologies, and anti-aging issues. A4M is a leading world provider of medical education, as its scientific promotion of anti-aging medical technologies will train more than 30,000 physicians via their two dozen separate physician education programs over the next 12 months worldwide. A4M seeks to disseminate information concerning innovative science and research as well as treatment modalities designed to prolong the human lifespan.

At the XIII Annual International Congress on Anti-Aging Medicine's Summer 2005 Session, a three-hour Panel Discussion shared "New Discoveries and Cutting-Edge Innovations in Medicine and Healthcare from America's Top Medical Journalists/Investigators and Newsletter Publishers." At this panel, key topics included freedoms in healthcare choices and the return to a focus on patient care.

Awards were presented to two distinguished physicians in recognition of their outstanding service to humanity:
- Presentation of the Medical Humanitarian Award by Dr. Robert Goldman, A4M Chairman, to Dr. Henry Heimlich, inventor of the lifesaving Heimlich Maneuver
- Presentation of the Lifetime Education Award by Dr. Robert Goldman, A4M Chairman, to Dr. William Lane, founder of the I.W. Lane College of Integrative Medicine

Today's mature adults control more than $7 trillion in wealth in the United States [Harvard Business Review, March 2004, or 70 percent of all US wealth. Further, they bring in $2 trillion in annual income and account for 50 percent of all discretionary spending." [Associated Press, March 7, 2004. At the co-located Chicago Anti-Aging Exposition, more than 300 corporate booths displayed the latest technologies from the medical and biotech market aimed at improving and/or extending the human lifespan. The United States market for anti-aging products and services exceeds $45.5 billion (2004). Growing at an average annual growth rate of 9.5 percent, this market will reach nearly $72 billion by 2009. [Business Communications Company, Inc., February 2005. Companies with products and services in the $7.7 billion appearance products and services market also were represented.

Remarks Dr. Robert Goldman, A4M Chairman: "This is the largest event of its kind in the world, and very much an interdisciplinary event as the program includes facets from endocrinology, spa medicine, plastic surgery and aesthetic medicine, sports medicine, and other fields of preventive healthcare. The XIII International Congress on Anti-Aging Medicine Winter 2005 Session is anticipated to be double in size  6,000 attendees and 600 corporate booths, representing the most innovative advancements in life enhancement and life extension medical technologies."

The XIII International Congress on Anti-Aging Medicine Winter 2005 Session and co-located Las Vegas Anti-Aging Exposition will take place 9-12 December 2005 at The Paris Hotel in Las Vegas, Nevada USA. For program details and online registration, visit http://www.worldhealth.net/event. For exhibit and sponsorship opportunities, contact the A4M Sales Department at (561) 392-7791 or send fax to (561) 338-1873.

The American Academy of Anti-Aging Medicine, Inc. ("A4M") is a non-profit medical society dedicated to the advancement of technology to detect, prevent, and treat aging related disease and to promote research into methods to retard and optimize the human aging process. A4M is also dedicated to educating physicians, scientists, and members of the public on biomedical sciences, breaking technologies, and anti-aging issues. A4M believes that the disabilities associated with normal aging are caused by physiological dysfunction which in many cases is ameliorable to medical treatment, such that the human lifespan can be increased, and the quality of one's life enhanced as one grows chronologically older. A4M seeks to disseminate information concerning innovative science and research as well as treatment modalities designed to prolong the human lifespan. Anti-Aging Medicine is based on the scientific principles of responsible medical care consistent with those of other healthcare specialties. Although A4M seeks to disseminate information on many types of medical treatments, it does not promote or endorse any specific treatment nor does it sell or endorse any commercial product.

Source: The American Academy of Anti-Aging Medicine (A4M), Chicago, IL




Biotech
Biotech
Entrepreneurs
Arizona SEO
Biotechnology News Forums
Biotech News
Biotech News
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
Iowans talk biotech with Chinese
Iowans talk biotech with Chinese



Biotechnology will be critical to feeding China’s growing population, said a key government official Aug. 10 at a forum with Iowa farmers in Beijing.

Truth About Trade & Technology - Iowans talk biotech with Chinese


“We need technology, especially biotechnology,” stated Dr. Hong Guang Wang, director general of the National Center for Biotechnology Development, Ministry of Science and Technology for the People’s Republic of China (PRC).

He addressed the Iowa Farm Bureau Federation (IFBF) board of directors at a China-U.S. Applied Biotechnology Forum held Aug. 10-11 in Beijing.

Food is a critical issue for one of the world’s most populous nations. Wang said imports of U.S. corn and soybeans will be needed.

“The United States is the largest producer in the world, so I think we need to work more and more closely together,” stated one of the government’s most influential scientific leaders.

Wang predicted that biotechnology in agriculture will bring a “Green Revolution” over the next 20 to 30 years, one “more powerful than the first revolution.”
“This meeting is quite important to us,” he stated.

Iowa Farm Bureau President Craig Lang succinctly stated the viewpoint of U.S. farmers on biotechnology.

Biotech
Biotech
Entrepreneurs
Arizona SEO
Biotechnology News Forums
Biotech News
Biotech News



Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
Biotech advance in grape controls - BOTRY-Zen
Biotech advance in grape controls


The New Zealand Herald

27.08.05

Dunedin biotechnology company BOTRY-Zen is looking to add another two biological controls to its product suite.

Chief executive John Scandrett told the company's annual meeting that it was evaluating the commercial prospects of two newly developed controls for grape diseases to add to its BOTRY-Zen biological control for the grape-wasting botrytis cinera fungus.

BOTRY-Zen has an agreement with the New Zealand Wine Institute and HortResearch for new products, and a $200,000 grant it has received from the Wine Institute will help with the evaluation.


Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] Worldwide Biotech & Pharmaceutical Obtains the China Patent Golden Medal For Its

------------------------ Yahoo! Groups Sponsor --------------------~-->
Get fast access to your favorite Yahoo! Groups. Make Yahoo! your home page
http://us.click.yahoo.com/dpRU5A/wUILAA/yQLSAA/H4xqlB/TM
--------------------------------------------------------------------~->

Worldwide Biotech & Pharmaceutical Obtains the China Patent Golden
Medal For Its 'Intact Hepatitis C Virus (HCV) and Method for
Culturing HCV in Vitro by Cell Culture'

Marks the Highest Award Over the Past 10 Years in the Biomedical
Sciences
Industry in China

XI'AN, China, Aug. 25 -- Worldwide Biotech &
Pharmaceutical Company (OTC Bulletin Board: WWBP) (''WWBP'') has
obtained the
China Patent Golden Medal for ''the Intact Hepatitis C Virus (HCV)
and Method
for Culturing HCV in Vitro by Cell Culture.''
The project ''The Intact Hepatitis C Virus (HCV) and Method for
Culturing
HCV in vitro by Cell Culture'' was awarded the Chinese Patent by
China Patent
Bureau on October 23rd, 2002. The patent was then awarded the
prestigious
China Patent Golden Medal (Chinese Patent No. 01124001.6) in the 8th
China
Patent Assessment organized by both General World Intellectual
Property
Organization (WIPO) and the China Patent Office. Importantly, this
patent was
recognized by the World Intellectual Property Organization (WIPO),
issued as
an outstanding Chinese Patented Invention, and was the highest award
issued
for achievements in the biomedical sciences industry over the past
10 years in
China.
''We are highly encouraged with our patent which is recognized
by the WIPO
and it is such a great achievement for the whole company. It's a
great
milestone,'' said WenXia Guo, CEO and President of WWBP, ''the
success of this
patented invention leads our company to a worldwide market, we will
continue
our development and research of new inventions and bring health to
every
customer.''

About World Intellectual Property Organization (WIPO)
The World Intellectual Property Organization (WIPO) is an
international
organization dedicated to promoting the use and protection of works
of the
human spirit. These works -- intellectual property -- are expanding
the
bounds of science and technology and enriching the world of the
arts. Through
its work, WIPO plays an important role in enhancing the quality and
enjoyment
of life, as well as creating real wealth for nations. With
headquarters in
Geneva, Switzerland, WIPO is one of the 16 specialized agencies of
the United
Nations system of organizations. It administers 23 international
treaties
dealing with different aspects of intellectual property protection.

About Worldwide Biotech & Pharmaceutical Company
Worldwide Biotech & Pharmaceutical Co. (''WWBP'') is a hi-tech
biotech
company with top-ranking pharmaceutical R&D abilities, Good
Manufacturing
Practices (GMP) licensed manufacturing facilities and a well-
established
marketing network in China and Southeast Asia. The product range of
WWBP
covers Hepatitis C Virus (HCV) products, diagnostic medicines and
Over-The-Counter (OTC) drugs. WWBP currently possesses 35,940
square meters
of land and 5,359 square meters of GMP standard facilities. With
strong
pharmaceutical R&D abilities especially in the HCV field, WWBP has
been known
as the first biotech company in the world to hold the technology of
culturing
intact HCV in vitro by cell culture.
WWBP has achieved a GMP production scale level of 10,000 ml for
concentrated HCV material and 10 grams HCV antigen per month, which
is
expected to bring WWBP considerable gross sale revenue each year and
greatly
strengthen the company's R&D on anti-HCV drug screen and HCV human
vaccine.
WWBP had successfully reached two Memoriam of Understanding of Merger
Agreements with pharmaceutical companies in China, all of which have
scalable
production and well-established sales networks, and the acquiring is
expected
to be finished before the end of September 2005. The acquisitions
will
strengthen WWBP's R&D abilities and production scale, as well as
extend its
marketing network throughout China and Southeast Asia. WWBP has
been working
closely with pharmaceutical research institutes, and has established
connections with both central & local governments.

Safe Harbor
Information in this news release may contain statements about
future
expectations, plans, prospects or performance of Worldwide Biotech &
Pharmaceutical Co. that constitute forward-looking statements for
purposes of
the safe harbor provisions under the Private Securities Litigation
Reform Act
of 1995. The words or phrases "can be," "expects," "may
affect," "believed,"
"estimate," "project," and similar words and phrases are intended to
identify
such forward-looking statements. Worldwide Biotech & Pharmaceutical
Co.
cautions you that any forward-looking information provided by or on
behalf of
Worldwide Biotech & Pharmaceutical Co. is not a guarantee of future
performance. None of the information on this website constitutes an
offer to
sell securities or investment advice of any kind, and visitors
should not base
their investment decisions on information contained in this website.
Worldwide
Biotech & Pharmaceutical Co.'s actual results may differ materially
from those
anticipated in such forward-looking statements as a result of various
important factors, some of which are beyond Worldwide Biotech &
Pharmaceutical
Co.'s control. In addition to those discussed in Worldwide Biotech &
Pharmaceutical Co.'s press releases, public filings, and statements
by
Worldwide Biotech & Pharmaceutical Co.'s management, including, but
not
limited to, Worldwide Biotech & Pharmaceutical Co.'s estimate of the
sufficiency of its existing capital resources, Worldwide Biotech &
Pharmaceutical Co.'s ability to raise additional capital to fund
future
operations, Worldwide Biotech & Pharmaceutical Co.'s ability to
repay its
existing indebtedness, the uncertainties involved in estimating
market
opportunities and, in identifying contracts which match Worldwide
Biotech &
Pharmaceutical Co.'s capability to be awarded contracts. All such
forward-looking statements are current only as of the date on which
such
statements were made. Worldwide Biotech & Pharmaceutical Co. does
not
undertake any obligation to publicly update any forward-looking
statement to
reflect events or circumstances after the date on which any such
statement is
made or to reflect the occurrence of unanticipated events.

SOURCE Worldwide Biotech & Pharmaceutical Company

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/
http://www.arizonaentrepreneurs.com/
http://www.azhttp.com/
http://www.arizonabiotech.com/index.php
http://www.mail-archive.com/biotech-news@yahoogroups.com/
http://www.mail-archive.com/biotech-
news@yahoogroups.com/maillist.html

http://www.arizonabiotech.com/
<a href="http://www.arizonabiotech.com/">Arizona Biotech</a>
http://groups.yahoo.com/group/biotech-news/
<a href="http://groups.yahoo.com/group/biotech-news/">Biotech News</a>
http://www.arizonaentrepreneurs.com/
<a href="http://www.arizonaentrepreneurs.com/">Arizona Entrepreneurs</a>
http://www.azhttp.com/
<a href="http://www.azhttp.com/">Arizona High Tech</a>

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] American Stock Exchange Lists Common Stock of Bodisen Biotech Incorporated

------------------------ Yahoo! Groups Sponsor --------------------~-->
Get fast access to your favorite Yahoo! Groups. Make Yahoo! your home page
http://us.click.yahoo.com/dpRU5A/wUILAA/yQLSAA/H4xqlB/TM
--------------------------------------------------------------------~->

American Stock Exchange Lists Common Stock of Bodisen Biotech
Incorporated


NEW YORK, Aug. 26 The American Stock Exchange(R) (Amex(R))
today listed the common stock of Bodisen Biotech, Incorporated,
under the ticker symbol BBC.
Bodisen Biotech, Inc. (the "Company" or "Bodisen") is
incorporated in the state of Delaware and is headquartered in the
Shaanxi Province of the People's Republic of China. Bodisen engages
in the business of manufacturing and marketing a brand of organic
fertilizer to the five leading agricultural provinces of China.

"Bodisen joins the growing number of international companies
that have chosen to list on the American Stock Exchange, and we are
pleased to have them," said John McGonegal, senior vice president of
the Amex Equities Group.
"We hope to provide them with the tools necessary to thrive as a
publicly-traded company in today's challenging marketplace."
The company has selected Kellogg Capital as its specialist. For
further
information on BBC and other Amex-listed companies, please visit
http://www.amex.com.

The American Stock Exchange(R) (Amex(R)) is the only primary
exchange that
offers trading across a full range of equities, options and exchange
traded
funds (ETFs), including structured products and HOLDRS(SM). In
addition to
its role as a national equities market, the Amex is the pioneer of
the ETF,
responsible for bringing the first domestic product to market in
1993.
Leading the industry in ETF listings, the Amex lists 165 ETFs to
date. The
Amex is also one of the largest options exchanges in the U.S.,
trading options
on broad-based and sector indexes as well as domestic and foreign
stocks. For
more information, please visit http://www.amex.com.

SOURCE American Stock Exchange
Web Site: http://www.amex.com

http://www.arizonabiotech.com/
http://groups.yahoo.com/group/biotech-news/

http://www.arizonabiotech.com/
<a href="http://www.arizonabiotech.com/">Arizona Biotech</a>
http://groups.yahoo.com/group/biotech-news/
<a href="http://groups.yahoo.com/group/biotech-news/">Biotech News</a>
http://www.arizonaentrepreneurs.com/
<a href="http://www.arizonaentrepreneurs.com/">Arizona Entrepreneurs</a>
http://www.azhttp.com/
<a href="http://www.azhttp.com/">Arizona High Tech</a>

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
NIH eases ban on employees owning drug, biotech stock - The Boston Globe
NIH eases ban on employees owning drug, biotech stock - The Boston Globe

NIH eases ban on employees owning drug, biotech stock
By Kevin Freking, Associated Press | August 26, 2005

WASHINGTON -- Officials at the National Institutes of Health said yesterday that rules designed to reduce conflicts of interest at the agency went too far, so they eased a prohibition on owning stock in pharmaceutical and biotechnology companies for thousands of employees.

Article Tools
Printer friendly
E-mail to a friend
Nation RSS feed
Available RSS feeds
Most e-mailed
Reprints/permissions
More:
Globe Nation stories |
Latest national news |
Globe front page |
Boston.com
Sign up for: Globe Headlines e-mail | Breaking News Alerts Under the new regulation, about 200 senior employees as well as their spouses and minor children will be prohibited from owning more than $15,000 worth of such stock. Any holdings above that amount will have to be sold by Jan. 30.

But an interim rule issued in February would have had a much broader impact.

Under that rule, about 6,000 scientists and other high-ranking employees would have been required to sell their stock holdings in such companies entirely. An additional 12,000 employees would have been required to keep such holdings to a maximum of $15,000 in value.


Biotech
Biotech
Entrepreneurs
Arizona SEO
Biotechnology News Forums
Biotech News
Biotech News
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] Novel lipoplex nanoparticle to be used in 1st human trial treating advanced soli

Novel lipoplex nanoparticle to be used in 1st human trial treating
advanced solid cancer
Washington D.C. -- The first clinical trial of a biologic
nanoparticle designed to give back to cancer patients the tumor-
busting gene they have lost is expected to start in September at
Georgetown University Medical Center.
The phase I clinical study will enroll 20 patients with advanced
solid cancers (including most common tumor types), and is the
culmination of more than a decade of work by a team of researchers
led by Professor Esther H. Chang, Ph.D. at the Lombardi
Comprehensive Cancer Center.

Their research has led to development of a tiny structure --
measuring a millionth of an inch across -- that resembles a virus
particle that can penetrate deeply into the tumor and move
efficiently into cells. The device is a "liposome" -- a microscopic
globule made of lipids -- that is spiked on the outside with
antibody molecules that will seek out, bind to, and then enter
cancer cells including metastases wherever they hide in the body.
These molecules bind to the receptor for transferrin that is present
in high numbers on cancer cells.

Once inside, the nanoparticle, which the researchers call
a "immunolipoplex," will deliver its payload -- the p53 gene whose
protein helps to signal cells to self-destruct when they have the
kind of genetic damage characterized by cancer and by cancer
therapies.

More than half of all cancer patients have cancer cells that have
lost normal functioning of the p53 gene, so-called "guardian of the
genome," and the Georgetown researchers believe that restoring the
gene will improve the tumor-killing ability of traditional
treatments.

"We are excited about the promise this nanoparticle has shown in
animal tumor models, and are anxious to offer it to patients," said
Chang, Professor in the Department of Oncology and Co-director of
the Molecular Targets & Developmental Therapeutics Program at
Georgetown.

The federal Food and Drug Administration granted approval for the
trial to begin in late July. The work is being sponsored by grants
from the National Institutes of Health and private foundations.
Additional support comes from SynerGene Therapeutics, a biotech
research firm with which Chang collaborates.

John Marshall, M.D., Director of Developmental Therapeutics and GI
Oncology at Georgetown, will serve as the trial's principal
investigator.

The researchers believe that immunolipoplex represents an advance
over the viral "vectors" that have been used to deliver gene
therapy, because these liposomes do not produce the kinds of
immunologic response seen when disabled viruses are used to carry
the payload. They also say that the nanoparticle is of a small
uniform size and consistency, and has been proven to work in animals
bearing tumor.

In preclinical research, Chang and long-term research colleague
Kathleen Pirollo, Ph.D. have found that these nanoparticles
substantially improve the tumor-fighting power of both chemotherapy
and radiation therapy. These agents work synergistically with
traditional therapies because the newly restored p53 protein helps
push cancer cells that are now damaged to self-destruct.

"We believe this approach will make it difficult for the cancer
cells to become resistant to therapy," Chang said. "As a result,
cancers treated with these liposomal formulations should be less
likely to recur after therapy is complete."

For example, use of these p53-loaded liposomes in combination with
radiation therapy eliminated prostate and head and neck tumors in
mice, which then survived cancer-free for more than 200 days --
until they all died of old age. Similar promising results were seen
when the nanoparticles were combined with chemotherapy to treat
animal models of melanoma and aggressive breast cancer.

Among the solid tumors approved for testing in the clinical trial
are head and neck, prostate, pancreatic, breast, bladder, colon,
cervical, brain, melanoma, liver and lung cancers.

Arizona Biotech Biotech News Arizona Entrepreneurs
Arizona SEO Famous Quotes Biotechnology News Forums
Biotech News Biotech News
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] Pharmaceutical/Biotech Marketing Excellence: Leveraging the Sales Force to Drive

Pharmaceutical/Biotech Marketing Excellence: Leveraging the Sales
Force to Drive Re-Packaging, Re-Branding and Re-Launching Success

Winning and developing sales force excitement about a re-launch
product is critical to its success during re-launch. More than 65%
of benchmarked pharmaceutical and biotech organizations find
creating excitement, expanding coverage and enhancing incentives
most effective for placing the re-launched product in their sales
force(s), according to a recent study by pharmaceutical research
firm Best Practices, LLC. To drive sales enthusiasm, executives
involve sales leaders from the field at every stage of planning to
ensure complete understanding of the business case for re-launch.
Obtaining sales force buy-in is a change movement process, but
involvement is a critical lever that can be used to impact overall
buy-in.

Best-Practices' study "Product Re-launch Excellence: Transforming
Lackluster Pharmaceutical Products into Market Success Stories" --
complimentary summary available at www3.best-in-class.com/rr605.ad --
provides insights into how leading companies win the hearts and
minds of their sales organization. For example, poor sales force
training at one company was responsible for a lackluster first
launch. As a result, the brand team is now using a distance
education program, from which the team has seen some positive
results.

In addition to insights into re-launch sales force management, this
study also provides a comprehensive overview of field-proven re-
launch strategies, practices and experiences from 14 leading
pharmaceutical and biotech companies in the following critical
areas:

* Setting Re-launch Strategy -- A leading company needed to cut
the price
to re-launch its lackluster drug. However, the sales
organization was
resistant to the proposed cut due to fears of increased
difficulty in
meeting the sales quota. To win their support, the brand team
made the
case to the sales organization that increased volume of sales
would
easily make up for the lower price.
* Re-defining Product Character -- 95% of surveyed companies find
adjusting core message effective or highly effective for
redefining
brand character and brand story in the marketplace.
* Re-launch Marketing Investment Metrics: Companies essentially
share the
same approach to resource allocation for re-launching: the
majority of
investment -- roughly 75% -- is shared by sales, various
promotional
channels, KOLs and advocacy initiatives.
* Case Studies: Read about what made the re-launches of
Zithromax &
Wellbutrin XL so successful.

The research findings are drawn from surveys and interviews of
executives from leading companies including: Abbott Laboratories,
AstraZeneca, Aventis, Eli Lilly, GlaxoSmithKline, Merck, Novartis,
Pfizer and Roche.

To download a complimentary summary or purchase the full
report, "Product Re-launch Excellence: Transforming Lackluster
Pharmaceutical Products into Market Success Stories," visit
www3.best-in-class.com/rr605.ad .

ABOUT BEST PRACTICES, LLC

Best Practices, LLC, a pharmaceutical research and consulting firm,
conducts work based on the principle that organizations can chart a
course to superior economic performance by studying the best
business practices, operating tactics and winning strategies of
world-class organizations.

Arizona Biotech Biotech News Arizona Entrepreneurs
Arizona SEO Famous Quotes Biotechnology News Forums
Biotech News Biotech News
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] Northeastern University President Richard Freeland To Step Down; Board of Truste

Northeastern University President Richard Freeland To Step Down;
Board of Trustees Chair Praises Freeland's Decade of Leadership

BOSTON--(BUSINESS WIRE)--Aug. 24, 2005--Northeastern University
President Richard M. Freeland has informed the University's Board of
Trustees of his intention to step down at the end of the 2005-06
academic year, which will be the tenth year of his presidency.

Dr. Freeland's tenure as President has been a transformative period
for Northeastern.

When appointed in 1996, President Freeland was charged by the Board
with repositioning Northeastern, moving it from the commuter school
it was viewed as to a university more selective in admissions, more
ambitious in scholarship, and more national in influence. The most
telling symbol of the university's success in accomplishing these
goals has been Northeastern's rise in the annual US News ranking
of "best national colleges." In the last five years, the university
has made steady progress, rising from 150 in 2002 to 115 in 2006.
The 2005 and 2006 scores placed Northeastern in the top tier of the
rankings for the first time in its history. For the fall of 2005,
over 25,000 students applied for just 2800 freshman places.

Freeland expressed pride that Northeastern's transformation has been
accomplished by focusing on the University's core values as
a "student-centered, practice-oriented, and urban" institution. The
University's flagship co-op program has been retooled to emphasize
its contribution to student learning. Engagement with the urban
community has been extended and deepened through partnerships to
build affordable housing in Roxbury, provide health care in
community-based centers, and train teachers for the city's schools.
Attention to student development has continued to be Northeastern's
central focus. The financial aid budget has increased by over 300%
in the last ten years to keep the university accessible to students
of limited financial means.

Freeland has given particular emphasis to establishing Northeastern
as a national leader in "practice-oriented education," an approach
to student development that integrates classroom study with
workplace experience and academic work in the liberal arts and
sciences with studies in professional disciplines. In a 2004 article
in the Atlantic Monthly titled "The Third Way," Freeland argued that
practice-oriented education is achieving recognition as a powerful
alternative to more traditional educational approaches at some of
the nation's leading academic institutions.

During Freeland's years the University's academic, scholarship and
research expertise has grown significantly. The University has made
thirteen appointments of nationally known scholars to named chairs
or distinguished professorships and has achieved growing success as
a center for research, particularly in applied fields. In 2000 the
campus was designated an Engineering Research Center by the National
Science Foundation--one of only twenty two such centers in the
country--to develop and commercialize technology in the fields of
sensing and imaging. Last year Northeastern was one of six
institutions nationally to be selected by NSF as a center for
research in Nanotechnology. A new Center for Drug Discovery is the
keystone of the University's $10 million Biotech Initiative. The
Center for Urban and Regional Policy and the Center for Labor Market
Studies are two of region's most important sources of policy-
oriented scholarship on urban issues. In 2003 the university
launched a five-year, seventy-five million dollar Academic
Investment Plan to expand the faculty by one hundred professors.

"On behalf of the Board of Trustees and the Northeastern University
community I wish to express our tremendous gratitude to President
Freeland for his tireless efforts and unwavering dedication to
Northeastern and to making this University shine in every way," said
Neal F. Finnegan, Chairman of the Board of Trustees. "The physical
and academic transformation of Northeastern that he has overseen has
been nothing short of spectacular in terms of the impact that it has
had on our student body and on the City of Boston."

During Freeland's tenure, the face of the University changed
dramatically. Traditionally characterized by plain, utilitarian
buildings surrounded by acres of parking lots, the campus has been
transformed into an attractive urban oasis. Since 1996, Northeastern
has invested $455 million in new facilities and has built ten
student residence halls, new homes for the colleges of Health
Science and Computer and Information Science, a recreation and
squash facility, and a high rise parking garage, and has created an
entirely new west campus. Much of this was made possible by a
successful $200 million capital campaign. Within the last three
years the university has received three major awards for design
excellence, including the 2005 Harleston Parker Medal from the
Boston Society for Architects who have designated Northestern's new
16-story residential tower as "the most beautiful building in Boston
within the last ten years."

President Freeland commented: "At the time of my appointment I said
that the Northeastern presidency was the best job in American higher
education. That statement holds true today. I have felt truly
blessed to be part of the most constructive and engaged colleague
community I have ever experienced. It has been an honor and a
privilege and I am grateful to all the members of the Northeastern
community that have worked so hard over the past ten years."

Board Chairman Finnegan indicated that the Trustees will be
announcing a selection process to name Freeland's successor within
the next several days. During the year ahead Freeland will work with
the Board to assure a smooth transition. A new president is expected
to be in place by the summer of 2006.

Freeland indicated that he had no definite plans for the
future. "For the moment, I am focused on the challenges of the year
ahead, including further pursuit of our top one hundred goal,
completion of the leadership campaign, and drafting our new physical
master plan." He continued, "I plan to use a sabbatical during 2006-
07 to think about the next phase. It has been a great ten years, but
a decade is about right for the presidency of a major university. It
is time to give someone else a chance to lead this terrific
University. As for me, I'll be 65 next year, so there is time for
another chapter. I am not retiring, but looking forward to the next
challenge."

Northeastern University
Highlights of the Freeland Years

1995 2005

National Ranking (US News and World
Report) 162 (1995 ed.) 115 (2006 ed.)
Endowment $282 (FY96) $558M (FY05)
External Funding $22M (FY96) $46M (FY05)
Applications Received for Freshmen
Admissions 11,800 (fall 95) 25,500 (Fall
05)
Acceptance Rate for Freshmen
Admissions 85% 47%
Average SAT Scores of Entering
Freshmen 1008 1224
Percent of freshmen in Top 10% of
High School Class 16% 36%
Percent of Freshmen from Outside
Massachusetts 49% 66%
Percent Freshman of Color 21% 25%
Freshman to Sophomore Retention
Rate 71% (Fall 95) 88% (Fall 04)
Freshmen Graduating in Six Years 39% (Spring 95) 60% (Spring 05)

Additional Information

-- Level of external funding increased more than 100% in the
last
ten years.

-- 13 appointments of nationally known scholars were made to
named chairs or distinguished professorships.

-- Successfully led a $200 million capital campaign, the largest
in the history of Northeastern.

-- Percentage of students in university housing increased from
33% (fall 95) to 50% (fall 04).

-- New programs and research centers were established including
the New Center for Drug Discovery, which is the keystone of
the University's $10 million Biotech Initiative and the
Center
for Urban and Regional Policy, which has become a cornerstone
of the university's work in public policy.

-- Recognition and awards included the following:

-- In 2002, the campus was designated an Engineering
Research
Center by the National Science Foundation.

-- In 2004, NU was one of six institutions to be selected by
the National Science Foundation as a center for research
in Nanotechnology.

-- Since 2002, NU has received three major awards for design
excellence including the 2005 Harleston Parker Medal from
the Boston Society of Architects.

-- In 2003, the first and only year in which this ranking
was
done by US News, Northeastern ranked #1 in the country
for
universities that connect classroom study and workplace
experience.

About Northeastern

Northeastern University, located in the heart of Boston,
Massachusetts, is a world leader in practice-oriented education and
recognized for its expert faculty and first-rate academic and
research facilities. Northeastern integrates challenging liberal
arts and professional studies with the nation's largest cooperative
education program. Through co-op, Northeastern undergraduates
alternate semesters of full-time study with semesters of paid work
in fields relevant to their professional interests and major, giving
them nearly two years of professional experience upon graduation.
The majority of Northeastern graduates receive a job offer from a co-
op employer. Cited for excellence four years running by U.S. News &
World Report, Northeastern has quickly moved up into the top tier
rankings - an impressive 35 spots in four years. In addition,
Northeastern was named a top college in the 2006 edition of the
Princeton Review's annual "Best Colleges" issue. For more
information, please visit http://www.northeastern.edu.

Arizona Biotech Biotech News Arizona Entrepreneurs
Arizona SEO Famous Quotes Biotechnology News Forums
Biotech News Biotech News
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] CeMines Expands Depth of the BioSystems Division Executive Management Team

CeMines Expands Depth of the BioSystems Division Executive
Management Team

Dr. Pauline Gee, Ph.D. Appointed Vice President and General Manager;
Anosheh Amery Appointed Vice President of Sales and Marketing

CeMines, Inc. today announced that Pauline Gee, Ph.D., (52), has
been appointed Vice President and General Manager of the Company's
BioSystems Division. Dr. Gee is responsible for the BioSystems
Division operations, P&L and building the recently announced product
management organization. In addition, CeMines also announced the
appointment of Anosheh Amery, (43), as Vice President of Sales and
Marketing for its BioSystems Division, reporting to Dr. Gee. The
appointments are effective immediately.

Dr. Gee joins CeMines from MDS Pharma Services, a contract drug
discovery company, where she was Vice-President of Predictive
Biology, responsible for directing the company's chemogenomics and
toxicogenomics efforts. Prior to joining MDS Pharma Services, Dr.
Gee was President and CEO of Xenometrix, Inc., a biotech company
pioneering gene expression profiling necessary to describe cellular
regulatory responses to compounds. She earned her doctorate in free
radical chemistry from Simon Fraser University, in British Columbia,
Canada. Her post-doctorate studies focused on analytical chemistry
and constructed Ames strains, which were patented in the
Biochemistry and Molecular Biology Division at the University of
California at Berkeley. Dr. Gee also did post-doctoral work in DNA
repair of neurons in the Biological Sciences Department at Stanford
University. Pauline will report to Roger Attick, CEO of CeMines,
Inc.

Anosheh Amery joins CeMines from Invitrogen, where he was
responsible for directing the launch of more than 15 new products.
He also managed new- business development, where his
responsibilities included the evaluation and strategic planning of
new business opportunities. In this roll Anosheh guided Invitrogen's
entry into the molecular diagnostics market. Prior to Invitrogen,
Mr. Amery was at QIAGEN, where he managed key clinical products for
the diagnostic, pharmaceutical, academia and HLA sectors. He
received a Bachelor of Science degree in Physiological Sciences from
UCLA. He then received an MBA from one of the most prestigious
graduate business schools in Europe, SDA Bocconni in Milan, Italy.

"CeMines has advanced our CellCorrect(TM) product family pre-market
development and clinical studies at a head-spinning pace," said
Roger Attick, CEO of CeMines, Inc. "At this stage of a company's
growth, it is critical to perform an introspective evaluation of
strengths and weaknesses. Our evaluation concluded it was time to
add key expertise and management depth." Mr. Attick then added: "We
are about to begin a substantial transition from R&D and prototypes,
to global commercialization of a novel family of clinical cancer
products. The time is now to adopt more disciplined and rigorous
product management, commercialization 'best-practices,' theranostics
platform R&D, and execute on our partnering strategy as we organize
clinical sales channels, international marketing alliances and
related distribution agreements."

About CeMines, Inc.

CeMines, Inc. is a Life Sciences Systems Biology company,
specializing in cell regulatory network research and molecular
diagnostics R&D that is principal to commercialization of novel
clinical products for worldwide use in diagnosis, treatment and
prevention of cancer. The company was founded in 2000 by Dr. Toomas
Neuman, Ph.D., Dr. Kaia Palm, Ph.D., and Mr. Richard Cavalli.
Company headquarters are located in Golden, Colorado. CeMines'
Diagnostics and Theranostics R&D is located in La Jolla, California,
and the company's European Union-based subsidiary of CeMines
International, CeMines Estonia OU, is located in Tallinn, Estonia.

Forward-Looking Statements

Any statements in this press release about future expectations,
plans or prospects for the company, including the company's
expectations and plans to complete the FDA review and clearance
process and CE Marking in the EU for CellCorrect LAb,
constitute 'Forward-Looking' statements. These statements involve
risks and uncertainties that may cause results to differ materially
from those set forth in these and previous statements. Forward-
looking statements should be evaluated along with other information
released by the company.

Biotech Arizona Biotech Arizona Entrepreneurs
High Tech Famous Quotations Biotechnology News
Biotechnology News Biotechnology News
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] Greer Adds Prominent Research Immunologist to Research and Development Team

Greer Adds Prominent Research Immunologist to Research and
Development Team

LENOIR, N.C. Aug 24, 2005 - Greer, a leading supplier of allergy
immunotherapy products and treatments, announced the addition of
research immunologist Fabien Lu, M.D., Ph.D. to Greer's Research and
Development Team. Included in Dr. Lu's many responsibilities will be
a primary focus around bringing his expertise to the oromucosal
research program. Prior to joining Greer, Dr. Lu worked in the
Virology and Immunology Unit of the California Regional Primate
Research Center at the University of California in Davis.

Dr. Lu's postgraduate work as a research immunologist has led to a
productive career with numerous peer-reviewed publications. He has
collaborated with scientists at major universities and biotech
companies to develop immunoassays for evaluating antibody and cell-
mediated immune responses. In 2002 Dr. Lu was presented an award by
the University of Alabama at Birmingham for his contributions in
molecular basis of NALT-induced mucosal immunity to SIV. He received
two more awards in 2002 and 2004 for his work studying
immunogenicity of rhesus monkeys.

"We are excited that Dr. Lu has chosen to join the Greer research
team," says Dr. Robert Esch, Greer vice president of research and
development. "With his experience and expertise, Dr. Lu will play an
integral role in expanding our research programs and developing our
second generation allergy immunotherapy products."

Dr. Lu began his career with a residency in medicine at Jilin
Medical University, Jilin, China, in 1985. He attended the Medical
University of Norman Bethune, Changchun, China, in 1987 in the field
of microbiology and infectious diseases. In 1991 Dr. Lu received a
master's degree in immunology and infectious disease from the
Pasteur Institute and University of Paris. He completed his Ph.D. in
1994 in immunology and virology while still attending the Pasteur
Institute.

About Greer

Greer, established in 1904 and located in Lenoir, North Carolina, is
a provider of allergy immunotherapy products and services for
treating humans and animals. Greer's highly skilled scientists
provide technical support for customers by continuing to focus and
improve the lives of allergic patients.

Biotech Arizona Biotech Arizona Entrepreneurs
High Tech Famous Quotations Biotechnology News
Biotechnology News Biotechnology News
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
Biotech policy to be formulated soon
Biotech policy to be formulated soon (RSSFeedReader)

Biotech policy to be formulated soon
By Staff Reporter
Aug 24, 2005, 12:13

A National Biotechnology Policy draft finalised recently awaits adoption, Science, Information and Communication Technology Minister Dr Abdul Moyeen Khan informed yesterday.

Addressing a conference on 'Biotechnology in Agriculture: Myths and Realities', Dr Khan said a taskforce headed by Prime Minister Begum Khaleda Zia has been formed to consider the policy that he expected to be transparent and easily comprehensible.

"The construction of National Biotechnology Institute to conduct research on latest issues is nearing completion at Savar. All these attempts categorically indicate how much importance the government has attached to this field," the minister said.

The conference jointly organised by the US Embassy in Dhaka and the Bangladesh Agricultural Research Council (BARC) at the Brac Centre in the city called for adoption of biotechnology in the country's agriculture to boost up production and feed the growing population.



Biotech Arizona Biotech Arizona Entrepreneurs
High Tech Famous Quotations Biotechnology News
Biotechnology News Biotechnology News
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
Drug firm moving to Boca Raton
Drug firm moving to Boca Raton

Drug firm moving to Boca Raton
By Stacey Singer

Palm Beach Post Staff Writer

Wednesday, August 24, 2005

UPDATED: 2:00 p.m. August 24, 2005

A small specialty drug company with offices in Buenos Aires, Argentina is moving its U.S. corporate headquarters from Wilmington, North Carolina to Boca Raton, the state's economic development agency, Enterprise Florida, announced Wednesday morning.

The firm, Osmotica Pharmaceuticals, has already moved seven executives from Wilmington to its new headquarters in the Sanctuary Centre at 4800 North Federal Highway in Boca Raton. Over the next three years, it expects its payroll to grow to about 25, said the company's chief financial officer, Richard E. Martin.

Scripps in South Florida
Post coverage of the biotech facility in Palm Beach County



State Sen. Ron Klein, D-Boca Raton, said the company's choice of Boca Raton showed that technology firms would move throughout the region, not just into the designated biotech parks that have been the focus of so much debate.



Biotech in Arizona Biotech Entrepreneurs
High Tech Arizona Famous Quotes Biotechnology News
Biotechnology News Biotechnology News
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
Leaders upbeat about progress in Winston-Salem - 2005-08-24
Leaders upbeat about progress in Winston-Salem - 2005-08-24

Bill Dean, president of Idealliance, spoke of development progress at the Piedmont Triad Research Park, where 342,000 square feet of space is already built and an additional 177,000 square feet is nearing completion.

"We are no longer fledgling," he said. "We're emerging. We're positioning ourselves correctly to do great things in Winston-Salem and the Piedmont Triad."

One item that could help biotech growth is that the city is close to finalizing a deal that would bring the N.C. State Biotech Conference to the Twin City next May, said Bob McCoy, president of the Winston-Salem Convention & Visitors Bureau.



Biotech Arizona Biotech Arizona Entrepreneurs
High Tech Famous Quotations Biotechnology News
Biotechnology News Biotechnology News
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
Biotech News
Biotech News
Biotech News


Arizona Biotech Biotech News Arizona Entrepreneurs
Arizona SEO Famous Quotes Biotechnology News Forums
Biotech News Biotech News
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
Biotech News
Biotech News
Biotech News


biotech news
biotech news
biotech news
biotech news
biotech news
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
Biotech News
Biotech News
Biotech News
Biotech News

Biotech News
Biotech News
Biotech News
Biotech News
Biotech News
Biotech News
Biotech News
Biotech News
Biotech News
Biotech News
Biotech News
Biotech News
Biotech News
Biotech News
Biotech News
Biotech News
Biotech News
Biotech News
Biotech News
Biotech News
Biotech News
Biotech News
Biotech News
Biotech News
Biotech News
Biotech News
Biotech News
Biotech News
Biotech News
Biotech News
Biotech News
Biotech News
Biotech News
Biotech News
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] Bodisen Biotech Announces Record Second Quarter Earnings of $0.17 per Share, 99%

Bodisen Biotech Announces Record Second Quarter Earnings of $0.17
per Share, 99% Increase in Revenue and 48% Increase in Net Income;
Bodisen Provides Earnings Guidance for 2005

NEW YORK Aug. 23, 2005--Bodisen Biotech, Inc. (OTCBB: BBOI, website:
www.bodisen.com) announced financial results for its second quarter
ending June 30, 2005. The following are some of the highlights as
reflected in its filing with the SEC:

Selected Second Quarter 2005 Results Compared to the Same Period in
2004

-- Revenue of $8,416,805, an increase of 99%

-- Net income of $2,692,014, an increase of 48%

-- Gross profit of $3,255,664, an increase of 64%

-- Basic earnings per share of $0.18 (fully diluted:$0.17), an
increase of 50% for basic earnings per share and 42% for fully
diluted

Selected First Half 2005 Results Compared to the Same Period in 2004

-- Revenue of $13,118,480, an increase of 104%

-- Net income of $3,488,746, an increase of 55%

-- Gross profit increased 72% compared to the six month period ended
June 30, 2004

-- Basic earnings per share of $0.23 (fully diluted: $0.22), an
increase of 53% for basic earnings per share and 47% for fully
diluted

REVENUE

Bodisen generated net revenue of $8,416,805 for the three month
period ending June 30, 2005, an increase of $4,186,600, or 99%,
compared to $4,230,205 for the same period in 2004. For the six
months ended June 30, 2005, the company reported net revenues of
$13,118,480 an increase of $6,702,186 or 104% compared to $6,416,294
for the comparable period in 2004. The increase in revenue was
primarily attributable to the completion of a new manufacturing
facility which had a major impact on manufacturing capacity, and a
renewed focus on marketing efforts as the company entered new
territories, resulting in increases in the customer base and related
volume of recurring and new customer sales.

NET INCOME

Bodisen reported net income of $2,692,014 for the three month period
ended June 30, 2005, an increase of $867,999, or 48% from
$1,824,015. For the six months ended June 30, 2005, Bodisen reported
net income of $3,488,746 an increase of $1,243,756 or 55% compared
to $2,244,990 for the comparable period in 2004. The increase was
attributable to the growth in demand for the Company's products as
they entered new markets throughout China.

EARNINGS GUIDANCE FOR YEAR 2005

Bodisen affirmed fiscal 2005 (December yearend) guidance for
earnings of approximately $8 million (including 1Q05 one time
financing related charge), or approximately 50 cents per share, on
revenue of approximately $28 million. Guidance does not include
positive impact from increased sales channels and further expansion
of manufacturing capacities, as a result of the Company's planned
dual listing before yearend on the AIM market of the London Stock
Exchange raising up to 10 million British Pound (US$18 million)
through placement of new shares (Broker: UK investment bank Charles
Stanley; Reporting accountant: Deloitte & Touche).

MANAGEMENT COMMENTS

Ms. Qiong Wang, Chairman and CEO of Bodisen commented: "We are
pleased that our second quarter results have exceeded our
expectations. Our new production facility has allowed us to meet
strong demand for our environmentally friendly organic fertilizer
products. The rapidly growing Chinese economy has lifted the
standard of living for 1.3 billion Chinese, including 900 million
farmers. Chinese consumers are very conscious of food quality. Many
Chinese only use foods and vegetables that are grown with organic
fertilizers although such foods are slightly higher priced. In order
to increase their household income, farmers across China demand
fertilizers that not only generate higher crop yields, but also are
organic and environmentally friendly. The year of 2005 should be
another banner year of strong earnings growth for Bodisen."

Ms. Wang continued her comment: "During the second half of 2005, in
addition to our continued focus on core business, Bodisen's
management is committed to increasing shareholder awareness. We look
forward to presenting Bodisen to US and European fund managers
through road shows in the fall."

About Bodisen Biotech, Inc.

Utilizing proprietary technologies, Bodisen sells over 60 packaged
products in 3 product categories: Organic Compound Fertilizer;
Organic Liquid Fertilizer; and Pesticides & Insecticides. Bodisen's
organic fertilizers can be absorbed by plants within 48 hours while
enriching soil conditions without the damaging effects associated
with chemical fertilizers.

Bodisen is headquartered in Shaanxi, China, an agricultural hub of
China and the economic gateway to the western regions of China. The
Bodisen brand is a highly recognized fertilizer brand in China. Its
environmentally friendly "green" products support the mandate of the
Chinese government to increase crop yields for the purpose of
decreasing China's dependency on food imports. Among China's
population of 1.3 billion, approximately 900 million Chinese are
farmers whose income depend on their crop yields.

Safe Harbor Statement

This press release may contain forward-looking statements within the
meaning of the "safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995. These statements are based on the
current expectations or beliefs of Bodisen Biotech, Inc. management
and are subject to a number of factors and uncertainties that could
cause actual results to differ materially from those described in
the forward-looking statements.

Arizona Biotech
Biotech News
Arizona Entrepreneurs
Arizona High Tech
Biotechnology News Forums
Biotech News
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] Nabi Biopharmaceuticals Appoints Leslie Hudson, Ph.D., to its Board of Directors

Nabi Biopharmaceuticals Appoints Leslie Hudson, Ph.D., to its Board
of Directors


- Pharmaceutical Executive Brings Scientific and Commercial
Experience to
Nabi Biopharmaceuticals' Board -

Nabi Biopharmaceuticals (Nasdaq: NABI) announced today that it has
elected Leslie Hudson, Ph.D., to its board of directors. Dr. Hudson
is currently president and chief executive officer of DOV
Pharmaceutical, Inc., and has served in several senior management
positions, including vice president of discovery research at Glaxo
Wellcome, group vice president and general manager at Phamacia Corp.
and executive vice president and chief operating officer at Repligen
Corp. With the addition of Dr. Hudson, Nabi Biopharmaceuticals'
board now totals eight members.

"Les brings a broad research background and commercial
experience in Europe and the United States that will be a tremendous
asset to our board of directors and company," stated Thomas H.
McLain, chairman, chief executive officer and president, Nabi
Biopharmaceuticals. "For more than 30 years, Les has held a number
of strategically important positions within the biotechnology and
pharmaceutical industries and in academia. We will benefit from his
expertise and experience in discovery research, product development
and commercialization at this significant point in Nabi
Biopharmaceuticals' strategic transformation."
Prior to DOV Pharmaceuticals, Dr. Hudson served as vice provost
for Strategic Initiatives at the University of Pennsylvania, where
he facilitated corporate partnerships and was responsible for
technology transfer and commercialization, corporate research and
development collaborations and regional economic development. Prior
to this position, he served in several positions at Pharmacia,
including senior vice president of research and exploratory
development, and senior vice president of emerging technology and
commercial development. He was also general manager and group vice
president of ophthalmology, where he was responsible for the
company's $1 billion ophthalmology business including the launches
of Xalatan, XalEase, Tecnis and Xalacom. Dr. Hudson also worked at
Glaxo in several senior research positions including head of cancer,
metabolic and hyperproliferative disease and vice president for
discovery research, in which he headed the company's genomics
program.
In addition to these corporate positions, Dr. Hudson has also
worked in
academia. He was a visiting scientist in the department of cell
biology at
Harvard University and head of the Department of Immunology at St.
George's
Hospital Medical School in London, where he taught for 12 years.
Dr. Hudson received his Ph.D. in immunology from the Imperial
College and
Middlesex Hospital Medical School at the University of London and
his B.A. in
zoology from the Imperial College of Science, Technology and
Medicine at the
University of London. He is also an associate of the Royal College
of Science
and has published more than 80 papers, books and articles on
immunology,
cancer and cell biology.

About Nabi Biopharmaceuticals
Nabi Biopharmaceuticals leverages its experience and knowledge
in powering
the immune system to develop and market products that fight serious
medical
conditions. We are poised to capture large, commercial
opportunities in our
core business areas: Gram-positive bacterial infections, hepatitis,
and kidney
disease (nephrology), and opportunistically in nicotine addiction.
We have
three products on the market today: PhosLo(R) (calcium acetate),
Nabi-HB(R)
[Hepatitis B Immune Globulin (Human)], and Aloprim(TM) [Allopurinol
sodium
(for injection)] and a number of products in various stages of
clinical and
preclinical development. The company filed its Marketing
Authorization
Application in Europe for its product candidate, StaphVAX(R)
[Staphylococcus
aureus Polysaccharide Conjugate Vaccine], in December 2004. The
application
was accepted for review in January 2005. StaphVAX is currently in a
confirmatory Phase III clinical trial in the United States.
StaphVAX is
designed to prevent the most dangerous and prevalent strains of S.
aureus
bacterial infections. S. aureus bacteria are a major cause of
hospital-
acquired infections and are becoming increasingly resistant to
antibiotics.
The company's other products in development include Altastaph(TM)
[Staphylococcus aureus Immune Globulin Intravenous (Human)], an
antibody for
prevention and treatment of S. aureus infections, NicVAX(TM)
[Nicotine
Conjugate Vaccine], a vaccine to treat nicotine addiction, and
Civacir(TM)
[Hepatitis C Immune Globulin (Human)], an antibody for preventing
hepatitis C
virus re-infection in liver transplant patients. For additional
information
on Nabi Biopharmaceuticals, please visit our website at:
www.nabi.com .

This press release contains forward-looking statements that
reflect the
company's current expectations regarding future events. Any such
forward-
looking statements are not guarantees of future performance and
involve
significant risks and uncertainties. Actual results may differ
significantly
from those in the forward-looking statements as a result of any
number of
factors, including, but not limited to, risks relating to the
possibility that
our confirmatory Phase III clinical trial for StaphVAX or our plans
to
commercialize StaphVAX in the European Union and United States may
not be
successful; the possibility that we may not realize the value of our
acquisition of PhosLo; the company's ability to raise additional
capital on
acceptable terms; the company's dependence upon third parties to
manufacture
its products; the company's ability to utilize the full capacity of
its
manufacturing facility; the impact on sales of Nabi-HB from patient
treatment
protocols and the number of liver transplants performed in HBV-
positive
patients; reliance on a small number of customers; the future sales
growth
prospects for the company's biopharmaceutical products; and the
company's
ability to obtain regulatory approval for its products in the United
States or
abroad or to successfully develop, manufacture and market its
products. These
factors are more fully discussed in the company's Annual Report on
Form 10-K
for the fiscal year ended December 25, 2004 filed with the
Securities and
Exchange Commission.

SOURCE Nabi Biopharmaceuticals
Web Site: www.nabi.com

Biotech
Biotech
Entrepreneurs
Arizona SEO
Biotechnology News Forums
Biotech News
Biotech News

SMS.ac sms.ac sms.ac sms.ac SMS.ac sms.ac sms.ac sms.ac sms.ac sms.ac sms.ac sms.ac sms.ac sms.ac sms.ac sms.ac sms.ac sms.ac sms.ac sms.ac sms.ac sms.ac sms.ac sms.ac sms.ac sms.ac sms.ac sms.ac sms.ac sms.ac sms.ac sms.ac sms.ac sms.ac
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] YaSheng Group's Biotech Science Research Center Patents Human DNA Technology Tha

YaSheng Group's Biotech Science Research Center Patents Human DNA
Technology That Is an Alternative to Antibiotics

The YaSheng Group (OTC: YHGG) achieved a breakthrough in Lysozyme
DNA Technology as reported by the company's Academy of Science
Research and Development Center. YaSheng was awarded the patent for
this newly developed technology under authorized patent
(ZL03100582.9) and International patent (C12N15/62). If sold for
$50/gram, YaSheng Group believes they can obtain annual sales of US
$525,000,000 from this Patent.

Scientists at YaSheng Group reported that the Lysozyme they
developed can eliminate Bacteria effectively without harmful side-
effects; a great alternative to existing antibiotics which limits
bacterial-growth. Lysozyme contains functions that strengthen the
immune system, reduce inflammation and cell growth with demonstrated
results in the prevention of oral cavity and respiratory tract.

The company reported a number of uses in this Lysozyme technology.
Lysozyme can be used as an antiseptic for the food industry and
serve as an essential additive to promote child growth. It can be
utilized in baby food, powered formula and drinks. Adding Lysozyme
to milk will make its characteristics closer to human milk.
Furthermore, Lysozyme can also be utilized in dairy farming as a
form of medication to prevent cow Mastitis. In the past, a common
practice to handle cow Mastitis was through elimination and
slaughter of herds, resulting in tremendous economic loss. Lysozyme
had proven to be an effective treatment to eliminate cow mastitis.

The YaSheng Group Academy of Sciences Research and Development
Center is in the process of applying Lysozyme DNA technology against
Acquired Immune Deficiency Syndrome (AIDS HIV). This research had
received strong support by the Chinese Government to further address
the rising issue in China. Clinical medication for AIDS is typically
expensive and is limited to only controlling the condition while
contributing serious side effects. The scientific research team of
YaSheng hopes to develop a new alternative for the treatment of
(AIDS HIV-1) by creating cell activities which causes a high
resistance to AIDS.

The market potential for Lysozyme is tremendous because of its
flexibility, multiple applications and numerous benefits. It is not
currently produced on an industrial level and is regarded highly by
the bio-medical community. YaSheng plans to further enhance the
development of Lysozyme and plans to utilize this new technology
across a number of the company's subsidiaries. The company's
pharmaceutical division had produced transgenic Lysozyme plants as
an herbal and food product with strong properties in health. In
addition, YaSheng will apply the new technology to agricultural
fields for improvement of crop varieties and increase ability to
resist bacteria in plants.

Additional uses for this patent can be viewed at:

www.yashenggroup.com/news_human_lysozyme.htm

About YaSheng Group:

The YaSheng Group (OTC: YHGG), a diversified industrial conglomerate
incorporated in Redwood City, California, operates in hi-tech
agriculture, salt chemistry and biological technology as its core
business with advantages in land, mineral resources, capital and
technology reserves.

Through its 136 subsidiaries, the company operating categories
include: chemical engineering, agricultural production, biotech,
pharmaceuticals, textile products, commercial trading, beverages and
inorganic salt manufacturing. With total assets of approximately
$1.5 billion USD and over 15,000 employees, YaSheng Group has
155,097,355 shares issued and outstanding as of December 1, 2004.

Further information concerning YaSheng Group can be found on the
corporate website: www.yashenggroup.com

Forward-Looking Statements:

Certain statements contained in this press release are forward-
looking statements that involve risks and uncertainties. The
statements contained herein that are not purely historical are
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended and Section 21E of the Securities
Exchange Act of 1934, as amended.

Biotech
Biotech
Entrepreneurs
Arizona SEO
Biotechnology News Forums
Biotech News
Biotech News

SMS.ac sms.ac sms.ac sms.ac SMS.ac sms.ac
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] Research and Markets : Future Outlook for Genzyme within the Biotechnology Secto

Research and Markets : Future Outlook for Genzyme within the
Biotechnology Sector

DUBLIN, Ireland--(BUSINESS WIRE)--Aug. 22, 2005--Research and
Markets (www.researchandmarkets.com/reports/c23064) has announced
the addition of PharmaVitae 2005: Genzyme Global Analysis to their
offering.

This analysis examines the current position and future outlook for
Genzyme in the biotechnology sector. The profile encompasses global
company strategy, portfolio and pipeline analysis and assessment of
financial performance, with 1-6 year sales forecasts for key drugs.
An interactive forecasting and analysis tool provides continually
updated quantitative and qualitative information.

Reasons to Purchase

Benchmark Genzymes performance against key rivals in the
biotechnology sector

Understand the impact of Genzymes M&A strategy

For more information visit www.researchandmarkets.com/reports/c23064

Biotech
Biotech
Entrepreneurs
Arizona SEO
Biotechnology News Forums
Biotech News
Biotech News

SMS.ac sms.ac sms.ac sms.ac
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] Tim Pawlenty and BIO's Jim Greenwood to Speak at BIO Mid-America VentureForum

Gov. Tim Pawlenty and BIO's Jim Greenwood to Speak at BIO Mid-
America VentureForum


Minnesota Governor Tim Pawlenty will join Jim Greenwood, president &
CEO of the Biotechnology Industry Organization (BIO), to address the
BIO Mid-America VentureForum at the Minneapolis Hilton on the
morning of Sept. 22. The forum, which runs Sept. 21-23, also
features luncheon keynote speeches from Leon O. Moulder, president
and CEO of Minneapolis-based MGI Pharma Inc., and Joshua Boger,
Ph.D., chairman, president and CEO of Vertex Pharmaceuticals Inc.,
of Cambridge, Mass.

Governor Pawlenty's commitment to biomedical research and
economic development led him to spearhead the creation of the
Minnesota Partnership for Biotechnology and Medical Genomics, a
unique enterprise linking expertise and resources from the Mayo
Clinic, the University of Minnesota and the state of Minnesota. His
other achievements since being elected governor in 2002 include
balancing the budget, overhauling education standards, welfare
reform, lawsuit reform, government efficiency initiatives, and
transportation improvement.

Insights on the national outlook for the biotechnology industry
will come
from Mr. Greenwood, who represented Pennsylvania's Eighth District
in Congress
before joining BIO in January. As a congressional leader on health
care
issues, he authored numerous bills signed into law, including
legislation to
promote pediatric labeling for pharmaceuticals, reform medical
device review
and approval, and expand research and establish innovative programs
to address
traumatic brain injury. Mr. Greenwood's top priority at BIO has been
improving the advocacy operation as the organization deals with
issues
encompassing the FDA, Medicare, intellectual property, and
agriculture and
energy policy.
The two luncheon keynote speakers, Mr. Moulder and Dr. Boger,
will offer
the perspective of successful biotech CEOs whose companies have
brought
innovative new therapies to patients. Other BIO Mid-America
speakers include
executives from top life sciences companies such as Johnson &
Johnson, Boston
Scientific and Genentech, and some of the nation's leading venture
capital
firms.

About BIO Mid-America VentureForum
Now in its third year, the BIO Mid-America VentureForum is the
Midwest's
largest annual event joining private biotech and medical device
companies in
need of funding with venture capitalists, angel investors, and
investment
bankers from across the United States and Canada. More than 60
private life
sciences companies will give business plan presentations during the
conference.
BIO Mid-America also features eight workshops and panel sessions,
including a Sept. 23 plenary session that will consider whether life
sciences
are at an inflection point in the Midwest. Other session topics
include
emerging markets, converging technologies, intellectual property,
reimbursement and the outlook for financing and partnering.
Complete information, as well as on-line registration, is
available at
bma.bio.org. Registration is complimentary for credentialed media.
In addition to BIO, the Mid-America VentureForum is co-sponsored
by
Medical Alley/MNBIO and eight state biotech associations: the
Colorado
BioScience Association, the Illinois Biotechnology Industry
Organization, the
Indiana Health Industry Forum, the Iowa Biotechnology Association,
MichBio
(Michigan), the Missouri Biotechnology Association, Omeris (Ohio),
and the
Wisconsin Biotechnology Association.

About BIO
The Biotechnology Industry Organization (BIO) represents more
than 1,100
biotechnology companies, academic institutions, state biotechnology
centers
and related organizations in all 50 U.S. states and 33 other
nations. BIO
members are involved in the research and development of health-care,
agricultural, industrial and environmental biotechnology products.
For more
information on BIO, visit our Web site at www.bio.org.

SOURCE Biotechnology Industry Organization
Web Site: www.bio.org bma.bio.org

Biotech
Biotech
Entrepreneurs
Arizona SEO
Biotechnology News Forums
Biotech News
Biotech News

SMS.ac sms.ac sms.ac sms.ac
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] Icogenex Expands Its Biotech Incubator Space

Icogenex Expands Its Biotech Incubator Space


SEATTLE, Aug. 22 /PRNewswire/ -- Icogenex Corporation announced
that it has expanded its biotech incubator space available for
sublease to start-up biotech companies.

Icogenex supplies full service biotech incubator space including
office and laboratory space as well as access to equipment for
molecular and cell biology investigations. This includes sterile
hoods, cell culture incubators, chemical fume hoods, glass wash and
autoclaving services, as well as centrifuges, PCR machines, water
bathes, and other equipment essential for basic molecular or cell
biology work. According to Dr. Frederick S. Hagen, founder,
President, and CEO of Icogenex, "With the acquisition of disposable
supplies, companies subleasing space in our facility have immediate
access to large and small laboratory equipment and can begin
experimentation within a few days." In addition, there are
intangible benefits to Icogenex sublessees of advice and counseling
from Icogenex executives who have many years of experience in the
biotech and pharmaceutical industries.

Icogenex's biotech incubator facility space supplies a niche
market to
start-up companies who are not yet highly capitalized. These
companies may be
financed with Small Business Innovation Research (SBIR) or Small
Business
Technology Transfer (STTR) grants from the National Institutes of
Health
(NIH), may have small amounts of independent financing in place, or
want a
fast start with venture investment funds. At these early stages, it
is often
very difficult to acquire all the equipment and secure independent
space for
initial operation. By subleasing biotech incubator space, a small
business is
able to provide proof of principle of their idea on a very low cost
budget,
allowing them to leverage their idea to greater capitalization. Dr.
Hagen
stated, "I know how difficult it was to find good biotech incubator
space when
I was founding Icogenex and how grateful I was when I secured the
initial
space."
Icogenex has been supplying biotech incubator space to start-up
biotech
companies in the Seattle area since 2002. Initially many of these
companies
are one to two person businesses. As they grow they rent additional
space from
Icogenex and eventually move out to larger independent facilities.
In addition to its biotech incubator business, Icogenex as a
Seattle-
based, privately held company is identifying and developing
therapeutic
compounds for the treatment of human diseases.

SOURCE Icogenex Corporation
Web Site: www.icogen.com

Biotech
Biotech
Entrepreneurs
Arizona SEO
Biotechnology News Forums
Biotech News
Biotech News

SMS.ac sms.ac sms.ac sms.ac SMS.ac sms.ac
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
ECI Biotech of Worcester, MA secures $2.5 Million in Private Equity Funding, strengthening initiative to develop simple, inexpensive diagnostics.
ECI Biotech of Worcester, MA secures $2.5 Million in Private Equity Funding, strengthening initiative to develop simple, inexpensive diagnostics.

Worcester, Mass. -- ECI Biotech recently secured $2.5 million in private equity funding, closing its Series C financing round. Since ECI President Dr. Mitchell Sanders founded the company in 1998, ECI Biotech has raised $5 million in private equity funding, signed collaborative partnerships ($6.5M) with Fortune 500 companies and secured Small Business Innovative Research Funding (SBIR $198,000). In addition ECI Biotech has 17 patents pending and one patent issued.

This latest round of funding solidifies ECI Biotech’s position at the forefront in the research and development of new protein technologies, strengthening ECI’s initiative to build simple and inexpensive diagnostics. Notes Dr. Sanders, “We have been able to attract private equity financing with very little effort due to our strong IP portfolio. This investment provides us with the capital to allow ECI to develop significant royalty revenues from partnerships with Fortune 100 clients.”





ECI’s Trademarked “Express Detect” Sensors
ECI Biotech’s novel core technologies enable the rapid detection of proteins specific to microbial pathogens. ECI’s trademarked “ExpressDetect” chemistry is extremely sensitive, requiring only trace amounts of substrate per sensor, which lends itself to high volume manufacturing processes (e.g. ink jet printing).

“ECI sensors are simple enough for a four year old to diagnose an infection, safe enough to go right on the skin, and inexpensive enough to be incorporated into everything from dental floss to diapers,” explains Dr. Sanders. The company plans to expand its operations in 2005 in order to supply the trademarked “ExpressDetect” chemistry to partners in professional and consumer care.

ECI has incorporated its sensors into several different materials including cotton and non-woven fibers, nylon, polyurethane, and polyethylene. “ExpressDetect” sensors are low cost, simple, fast, and can be incorporated into products such as dressings, swabs, catheters, feminine pads, wipes or specimen containers. “Significant unmet needs for this technology exist in advanced wound care, IV therapy, urology, oral care, skin care, and women’s care,” Dr. Sanders added.

ECI Biotech recently received a prestigious 2005 New England Innovation Award presented by the Smaller Business Association of New England and a 2004 TechCitizenship award from Mass High Tech.

Innovations and Applications
ECI Biotech maintains executive offices and research facilities located at 6 Park Avenue, in Worcester, Massachusetts. The company, founded in 1998, engages in breakthrough research on protein design and expression. ECI is developing and licensing its protein technologies for use in a wide range of industries with unmet needs, including nosocomial infections, medical diagnostics, industrial chemistry and consumer goods. ECI Biotech's product pipeline currently includes a diagnostic sensor for urinary tract infections, as well as advanced wound care systems designed to provide early warning of emergent infections and to promote healing. ECI presently also has 2 corporate partnerships with Fortune 100 companies in the medical device industry.
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] Scientific Industries Announces Addition of Bellco Biotechnology Product Line

Scientific Industries Announces Addition of Bellco Biotechnology
Product Line

Scientific Industries Inc. (OTCBB:SCND) announced today that it has
agreed to add Bellco Biotechnology(r) spinner flasks and other
laboratory glassware to the product line currently offered by the
Company to its customers. Bellco Biotechnology, a supplier of
specialized and general laboratory glassware, has over 65 years of
experience serving the laboratory industry.

"In laboratories, Bellco Biotechnology glassware products are
frequently used together with Scientific Industries products; both
brand names are well respected for their individual technologies,"
noted Chere Griffin, Director of Sales and Marketing at Scientific
Industries. "We expect this addition will increase our visibility in
the global market."

About Scientific Industries

Scientific Industries manufactures and markets laboratory equipment,
including the world-renowned Vortex-Genie(r) 2 Mixer. Scientific
Industries' products are used by research laboratories, clinics,
pharmaceutical manufacturers, medical device manufacturers, and
other industries.

"Statements made in this press release that relate to future events,
performance or financial results of the Company are forward-looking
statements which involve uncertainties that could cause actual
events, performance or results to materially differ. The Company
undertakes no obligation to update any of these statements. Readers
are cautioned not to place undue reliance on these forward-looking
statements, which speak only as to the date hereof. Accordingly, any
forward-looking statement should be read in conjunction with the
additional information about risks and uncertainties set forth in
the Company's Securities and Exchange Commission reports, including
our annual report on Form 10-KSB."

Biotech
Biotech
Entrepreneurs
Arizona SEO
Biotechnology News Forums
Biotech News
Biotech News

SMS.ac sms.ac sms.ac sms.ac
Biotech News 1 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] Patents for protein biomarker Discovery

Patents for protein biomarker Discovery
Peakadilly receives multiple patents for breakthrough Protein
biomarker discovery and identification technologies
The patent offices of the United States of America and Canada have
granted patents for Peakadilly's core technology, COFRADIC®.
COFRADIC® allows the identification and quantification of proteins
in any biological sample and represents the most important component
of the company's MASStermind® biomarker discovery engine. Peakadilly
has already received patents for the technology in Europe.
Peakadilly's proprietary proteomics technologies allow fast,
automated and highly flexible and sensitive qualitative and
quantitative proteomics without using gels and without the use of an
affinity tag. Together with a novel serum depletion technology and
state-of-the art mass spectrometry, Peakadilly's MASStermind®
platform allows to analyse huge sets of proteins and
posttranslational modified proteins in clinical samples like blood
or sputum, offering unrivalled sensitivities and high content data
unseen with genomics & transcriptomics. Using software tools
developed in-house, the quantitative comparison of hundreds of
samples is possible, making the technology suited for biomarker
discovery within clinical trials. In collaboration with a big pharma
company, the technology is currently being applied to distinguish
responders from non-responders in a specific therapeutic regimen.

Biotech
Biotech
Entrepreneurs
Arizona SEO
Biotechnology News Forums
Biotech News
Biotech News

SMS.ac sms.ac sms.ac sms.ac
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] Debiopharm and DeveloGen Announce Partnering of Myasthenia Gravis Program

Debiopharm and DeveloGen Announce Partnering of Myasthenia Gravis
Program

LAUSANNE, Switzerland and GOETTINGEN, Germany, August 16

Debiopharm S.A., the independent drug development company
specialising in oncology, endocrinology and niche products and
DeveloGen AG, a biopharmaceutical company focusing on novel
treatments for metabolic disorders, today announced an exclusive
worldwide collaboration and licensing agreement, by which Debiopharm
will develop PTR-262, a novel peptide drug for the treatment of
myasthenia gravis (MG), before out-licensing to global partners for
commercialisation.

Under the terms of the agreement, DeveloGen will receive
milestone payments and, upon commercialisation of the product,
royalties based on Debiopharm's revenues from worldwide sales.

Rolland-Yves Mauvernay, President and CEO of Debiopharm
said, "PTR-262 is a novel approach that may replace the currently
used immunosuppressive drugs and avoid the side-effects that
myasthenia gravis sufferers may experience.

PTR-262 will be the first disease-modifying drug for the treatment of
myasthenia gravis, as it aims at specifically abrogating the
production of disease-causing antibodies. This represents a
significant improvement over current therapies and a promising
treatment for myasthenia gravis patients".

Guenther Karmann, CEO of DeveloGen said: "We are very pleased
that Debiopharm has chosen to continue the development of PTR-262 as
a potential treatment for this debilitating disease. We are
confident that Debiopharm's extensive experience will ensure the
rapid advancement of PTR-262 into the market".
The PTR-262 program
PTR-262, discovered at the laboratories of Professors Michael
Sela and Edna Mozes at the Weizmann Institute of Science, Rehovot
Israel, is a
synthetic peptide which down regulates immune responses associated
with myasthenogenic peptides. PTR-262 is derived from the
myasthenogenic epitopes of the acetylcholine receptor (AChR) alpha-
subunit, which specifically arrests the autoimmune destruction of
AChR.
In preclinical models of MG, treatment by PTR-262 creates a
shift in the immune system from a Th1 to a Th2/Th3 response,
resulting in significant improvement of a number of clinical
parameters including grip strength and electromyography.
Furthermore, in peripheral blood serum derived from MG patients, PTR-
262 inhibits the proliferation of T-cell populations that are
responsible for myasthenogenic autoimmune mediated reactions and
thus the development of MG.
About Myasthenia Gravis
MG comes from the Greek and Latin words meaning, "grave muscular
weakness." The most common form of MG is a chronic autoimmune
neuromuscular
disorder that is characterized by fluctuating weakness of the
voluntary
muscle groups. MG is characterized by T-cell mediated autoantibody
attacks on
the AChR at neuromuscular junctions, causing weakness and fatigue of
cranial
and skeletal muscles. MG has a prevalence of 15/100,000 population,
with
approximately 36,000 cases in the United States. Available treatment
options
include cholinesterase inhibitors, immunosuppressive medication,
plasma
exchange and thymectomy, all with substantial side effects and which
do not
address the underlying cause of the disease. MG meets the criteria
for an
orphan disease with significant unmet medical need.
About Debiopharm
Debio is an established group of five complementary companies,
Debiopharm, Debioinnovation, Debio R.P., Debioclinic and H3 Pharma.
Debiopharm, founded in 1979 in Lausanne, Switzerland, focuses on
evaluating
compounds with promising in-vivo results in animals to in-license,
develop
for global registration, and out-license to sales and marketing
pharmaceutical partners. Debiopharm has proven expertise in drug
development,
having registered three products: Eloxatin(R), one of sanofi-
aventis' leading
marketed products, Decapeptyl(R), the leading product of Ipsen, and
Trelstar(R) (1-and 3-month) a registered trademark of Watson
Pharmaceuticals,
Inc. Together, their combined sales were in excess of $1.8 bn in
2004.
Debioinnovation was set up to complement the core business
objectives of
Debiopharm through addressing the financing and partnering needs of
biotechnology, pharmaceutical start-up companies and life science
incubators.
Debio R.P. is a leader in polymer-based controlled release
technologies that
allow certain drugs like proteins, peptides and anti-cancers to be
delivered
in customized, sustained-release formulation. From its FDA-inspected
manufacturing facility in Martigny, Switzerland, Debio R.P. also
conducts
feasibility studies, formulation selection, optimization, scale-up
and cGMP
manufacturing from clinical trial supplies to commercial scale.
Debioclinic,
based in Paris, is a contract research organization, specialized in
oncology
and dedicated to clinical development, providing regulatory,
biometric and
clinical support in line with cGCP. Montreal-based H3 Pharma is a
pharmaceutical product development company, focusing on oncology and
endocrinology. For more information on Debiopharm, please visit:
www.debio.com.
About DeveloGen
DeveloGen is a biopharmaceutical company focusing on the
development of
treatments for metabolic disorders, such as diabetes, obesity and
metabolic
syndrome. DeveloGen has a rich and innovative pipeline from lead
discovery to
phase II clinical development. DeveloGen's lead product DiaPep277
for the
treatment of type 1 diabetes and LADA (Latent Autoimmune Diabetes in
Adults)
is currently in late phase II clinical trials. DiaPep277 is a novel
immunomodulatory peptide derived from the heat shock protein hsp60,
which
protects the insulin producing beta cells from autoimmune
destruction. The
product Somatoprim is currently in preclinical development for the
treatment
of diabetic retinopathy. Further drug discovery approaches focus on
the
development of functional Pax4 agonists, secreted proteins and
synthetic
compounds aimed at the regeneration of the pancreatic beta-cell mass
for the
treatment of type 1 and type 2 diabetes. Proprietary targets in key
metabolic
pathways and inhibitors of key metabolic enzymes are developed by
functional
genomics based drug discovery for the treatment of type 2 diabetes,
obesity
and the metabolic syndrome. DeveloGen is headquartered in
Goettingen, with
additional sites in Rehovot, Israel, and Erkrath, Germany. For more
information on DeveloGen, please visit our website at
www.develogen.com.

SOURCE Debiopharm S.A.

Biotech
Biotech
Entrepreneurs
Arizona SEO
Biotechnology News Forums
Biotech News
Biotech News

SMS.ac sms.ac sms.ac sms.ac
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
Managing Information News
Managing Information News

iley To Launch Biotechnology Journal In January 2006

Global publisher John Wiley & Sons recently announced the January 2006 launch of Biotechnology Journal, a new international resource for biotechnology researchers and professionals in related disciplines. The journal will be published by Wiley-VCH, the company's subsidiary based in Weinheim, Germany.

Biotechnology Journal will publish peer-reviewed papers covering novel aspects and methods in all areas of biotechnology, especially those focusing on healthcare, nutrition, and technology. Special focus will also be given to the public, legal, ethical, and cultural aspects of biotechnological research.

"With the launch of Biotechnology Journal, Wiley-VCH will finally establish its own premier journal, building on the top-quality tradition of our Biotechnology Book Series and the highly successful concept of our journals such as Proteomics and Electrophoresis," said Dr. Carol Bacchus, Editorial Director for Life & Medical Sciences at Wiley-VCH. "Biotechnology Journal will fill the gap other journals leave in their coverage of biotechnology, and will meet the growing demand for an entirely new international publication that addresses all aspects of this rapidly-growing field."


Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] Pandemic Influenza Vaccine Development Accelerated at Generex Biotechnology with

Pandemic Influenza Vaccine Development Accelerated at Generex
Biotechnology with Hire of Accomplished Senior Scientist


Novel Vaccine Technology Boosts T Helper Cell Responses to Asian
Bird Flu Influenza, to Aid Some Existing Vaccines and for Use as a
Stand-Alone Vaccine in Developing Countries

TORONTO, Aug. 16 Generex Biotechnology Corporation (Nasdaq:
GNBT) announced today that Antigen Express, Inc., its
wholly owned immunotherapeutics subsidiary, hired Dr. John
Zinckgraf, Ph.D. to accelerate development of a novel vaccine for
pandemic influenza.

Dr. Zinckgraf received his Ph.D. in Molecular and Cellular
Biology from the University of Connecticut where his primary
research focus was DNA vaccine
development and delivery. He tested novel DNA vaccines for HIV and
HBV, using
various inducible and constitutive promoters as well as different
polyadenlylation sequences. Such genetic elements can regulate
antigen
synthesis and consequently the magnitude of the immune response to a
vaccine.
Following his doctoral work, Dr. Zinckgraf was as a postdoctoral
fellow at
Epimmune, Inc. in San Diego, California where he pursued pre-clinical
development of several infectious disease vaccines, using the
company's DNA
vaccine minigene technology. Dr. Zinckgraf returned to the
University of
Connecticut as a postdoctoral scientist to develop vaccine delivery
systems
for foot-and-mouth disease virus, as well as development and
expression of
single-chain antibodies against chemical and tobacco carcinogens.
Dr. Zinckgraf was recruited to Antigen Express in view of his
extensive
experience and strong track record in advancing vaccine
technologies. Dr.
Robert Humphreys, Chief Scientific Officer of Antigen Express, Inc.,
said,
"John is an excellent scientist who was recommended with highest
enthusiasm by
his mentors as a creative and hard working immunologist. In a few
short
months, he has greatly advanced the pace of our programs in
influenza and is a
superb strategic planner and experimentalist."
Dr. Zinckgraf said, "I am pleased to join the Antigen Express
group of
scientists. The technology is novel and recognized by senior
academic and
corporate scientists. We are making rapid progress toward testing a
series of
Ii-Key/T-helper cell epitope vaccines specific to protect against
the pandemic
form of Asian bird flu."
Dr. Zinckgraf explained further that his colleagues at Antigen
Express
have discovered that a segment of the Ii immunoregulatory protein
acts on the
antigenic peptide presenting molecules in a manner that boosts the
presentation of T-helper cell epitopes to the immune system. Using
such a
vaccine in humans could augment the response to subsequent
vaccination by a
flu virus vaccine or as a stand-alone vaccine to prevent viral
infection.
The Antigen Express team is developing a vaccine for pandemic
Asian bird
flu (H5N1 strain) based on H5 MHC class II epitopes, which have been
selected
for likelihood of being both potent and presented by many HLA-DR
alleles.
Ii-Key/MHC class II epitope hybrid peptides contain an
immunoregulatory
segment of the Ii protein (the Ii-Key moiety), loosening the epitope-
binding
groove of MHC class II molecules and permitting insertion of a
polymethylene-linked MHC class II epitope. Doing so increases the
potency of
epitope presentation 200 times in vitro, as measured in a T-cell
hybridoma
response assay. In addition, Ii-Key hybrids with principal MHC
class II
epitopes of various cancer and infectious disease antigens increase
the
T-helper cell response 4-8 times in vaccinated mice, as measured
using
purified CD4+ T cell IFN-Y ELISPOT assays. Presently, Antigen
Express has an
ongoing phase I clinical trial with Her-2/neu breast cancer
hybrids. Data
from these trials are relevant to establishing the safety and effect
of this
novel type of vaccine, for later use in validating an influenza
vaccine.
Anna Gluskin, CEO of Generex Biotechnology said, "I am very
pleased with
the rapid advance of this vaccine program. Our earlier work on
developing a
vaccine for the SARS virus put us into a forward position with
design concepts
and animal models for infectious disease. Now we are shifting focus
toward
the Asian bird flu vaccine because that threat is potentially so
gigantic. We
feel that this T-helper cell peptide vaccine might be all that is
available,
in a rapid time frame, for people in many parts of the world. It is
also an
excellent priming vaccine, to be used before or with other vaccines
which are
being developed."

About Generex
Generex is engaged in the research and development of drug
delivery
systems and technologies. Generex has developed a proprietary
platform
technology for the delivery of drugs into the human body through the
oral
cavity (with no deposit in the lungs). The Company's proprietary
liquid
formulations allow drugs typically administered by injection to be
absorbed
into the body by the lining of the inner mouth using the Company's
proprietary
RapidMist(TM) device. The Company's flagship product, oral insulin
(Oral-lyn(TM)), which has been approved for commercial sale in
Ecuador for the
treatment of patients with Type-1 and Type-2 diabetes, is in various
stages of
clinical trials around the world. Antigen Express is a wholly owned
subsidiary of Generex. The core platform technologies of Antigen
Express
comprise immunotherapeutics for the treatment of malignant,
infectious,
allergic, and autoimmune diseases.

For more information, visit the Generex Web site at
www.generex.com .

Safe Harbor Statement: This release and oral statements made
from time to
time by Generex representatives concerning the same subject matter
may contain
"forward-looking statements" within the meaning of the Private
Securities
Litigation Reform Act of 1995. These statements can be identified by
introductory words such
as "expects," "plans," "intends," "believes," "will,"
"estimates," "forecasts," "projects" or words of similar meaning,
and by the
fact that they do not relate strictly to historical or current facts.
Forward-looking statements frequently are used in discussing
potential product
applications, potential collaborations, product development
activities,
clinical studies, regulatory submissions and approvals, and similar
operating
matters. Many factors may cause actual results to differ from
forward-looking
statements, including inaccurate assumptions and a broad variety of
risks and
uncertainties, some of which are known and others of which are not.
Known
risks and uncertainties include those identified from time to time
in the
reports filed by Generex with the Securities and Exchange
Commission, which
should be considered together with any forward-looking statement. No
forward-looking statement is a guarantee of future results or
events, and one
should avoid placing undue reliance on such statements. Generex
claims the
protection of the safe harbor for forward-looking statements that is
contained
in the Private Securities Litigation Reform Act.

SOURCE Generex Biotechnology Corporation
Web Site: www.generex.com

Biotech
Biotech
Entrepreneurs
Arizona SEO
Biotechnology News Forums
Biotech News
Biotech News

SMS.ac sms.ac sms.ac sms.ac
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] Biotechnology Training in NC boosted by full funding for NCCCS BioNetwork

Biotechnology Training in NC boosted by full funding for NCCCS
BioNetwork

Raleigh - Legislators and the Governor showed their commitment to
promoting biopharmaceutical job education and training in North
Carolina by fully funding the North Carolina Community College
BioNetwork. In doing so, legislators made clear the importance of
growing 21st Century knowledge-based jobs in the state. North
Carolina is already ranked third in the US in biotechnology and is
home to some of the world's largest pharmaceutical and
biomanufacturing facilities. This industry creates about 3000 new
jobs a year in the state. The $7.1 million approved by the
legislature will sustain the momentum made by NCCCS BioNetwork in
providing the specialized workforce education and training that this
highly-regulated industry requires. Start-up funding for BioNetwork
was provided by Golden LEAF and continued funding from the
legislature was needed. North Carolina's Community College System
trains 70 percent of the workforce for the biopharmaceutical
industry, which has shown steady growth and is forecast to continue
doing so.

Community College System President H. Martin Lancaster said "one of
our System's highest priorities this session was to make sure that
the funding provided for in the past two years by the Golden LEAF
foundation to develop our BioNetwork was continued by a state
appropriation. We are pleased that the General Assembly fully funded
this request, recognizing the important role our colleges will be
playing in preparing the biotech workforce of the future. We also
appreciate the support of Golden LEAF during the past two years."

BioNetwork Director Susan Seymour thanked the legislature for its
leadership and foresight. "BioNetwork is closely watched by other
states and countries that realize the economic value our coordinated
approach provides to training for this industry. Last year's Milken
survey stated that the biopharmaceutical industry generated $1.3
billion for North Carolina. This legislative funding will help
BioNetwork retain, grow and attract this industry to North
Carolina," she said. "BioNetwork has already made an impact on site-
selection decisions, so this funding is strategic for North
Carolina."

Industry will also be pleased with the spending. In the past year,
already, the injection of funding from Golden LEAF into BioNetwork
enabled community colleges to ramp up training across the state.
Terence Novak, the Chief Marketing Officer for DSM, an international
contract manufacturer with a large facility in Greenville, NC, had
this to say at BIO International in Philadelphia; "BioNetwork has
been instrumental in helping us find a qualified workforce, and it
now takes much less time to train workers for our aseptic lines. Our
aseptic processing is state of the art, world class. It can take as
much as six months to train just one operator to go into the
facility to work on the line. The amount of time it takes now, with
BioNetwork, is much less and they can hit the ground running."

BioNetwork forms part of an initiative given $60 million in start-up
funding by Golden LEAF. The initiative, called the Biomanufacturing
and Pharmaceutical Training Consortium, is made up by the NCCCS
BioNetwork, North Carolina State University, and North Carolina
Central University. The consortium combines the resources of North
Carolina's university and community college systems to meet the
growing demands of the biotechnology and pharmaceutical industries.
NCCU will host BRITE - the Biomanufacturing Research Institute and
Technology Enterprise in a new building on its campus. NC State will
host the BTEC - the Biomanufacturing Training and Education Center -
a commercial scale pilot plant at its Centennial Campus and it will
share that space with BioNetwork. The BioNetwork Capstone Center
will provide workforce training at the BTEC in the dedicated
community college aseptic suite. The Capstone Center is already
offering highly technical training to industry at its interim
facility at Wake Tech, with courses such as Microbial Identification
and Operations in Biotechnology Processes.

Of the $8.7 million the Community College System received from
Golden LEAF, $6.4 million has been distributed via 65 competitive
grants to community colleges statewide. The grants enabled colleges
to buy the specialized equipment required to train workers for the
biopharmaceutical industry as well as develop specialized curricula
and short courses, provide faculty enhancement and launch a student
recruitment campaign. Six Centers were created, providing the
necessary infrastructure and support to assist community colleges
further develop the education and training they offer. This
networking has enabled community colleges to grow the numbers of
students and workers they can train and numbers have shown a
positive upward trend. It will also allow community colleges to
remain up-to-date with the needs of this fast-changing industry.
More about BioNetwork can be found at its website
www.ncbionetwork.org

Research shows that industry growth - as is typical elsewhere in the
US - is outstripping the numbers of trained workers. The continued
funding by the legislature will enable BioNetwork to address
this. "Not only will we meet industry's needs, if a company
considers opening a facility in North Carolina, we will be able to
give them the assurance that by the time they open their doors, we
will have a pool of trained workers from which they can choose,"
said Seymour.

Arizona Biotech
Arizona Biotech
Entrepreneurs
Arizona SEO
Biotechnology News Forums
Biotech News
Biotech News

SMS.ac sms.ac sms.ac sms.ac
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
Biotech industry seeks RM2bil grant for R&D
Biotech industry seeks RM2bil grant for R&D

Biotech industry seeks RM2bil grant for R&D

THE Malaysian BioIndustry Organisation hopes the Government will double the allocation for research and development (R&D) purposes under the 9th Malaysia Plan (2006-2010) to RM2bil from the RM1bil under the 8th Malaysia Plan.

According to chairman Datuk Dr Salleh Mohd Nor, the biotechnology industry requires substantial grants and incentives for it to become a major contributor to the Malaysian economy,

He said the sector should be given equal priority as the information and communications technology (ICT) industry in terms of government and financial support.


Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] Quark Biotech, Inc. Is the First Certified Service Provider for Agilent

Quark Biotech, Inc. Is the First Certified Service Provider for
Agilent Technologies' Array CGH (Comparative Genomic Hybridization)
Products


FREMONT, Calif., Quark Biotech, Inc. announced
today that the Company is the first Certified Service Provider for
Agilent
Technologies' (NYSE: A) microarrays to be certified for Array CGH
(Comparative
Genomic Hybridization) services. Quark was already a Certified
Service
Provider for Agilent gene expression microarrays.
This additional Agilent certification confirms Quark's continued
ability
to provide complete premium DNA microarray services. Certification
for the
Agilent program was granted once Quark's personnel completed a
training
program and the laboratory, as a whole, passed a rigorous set of
assessments.
The Certified CGH Service Quark provides includes sample receipt,
labeling and
the use of Agilent's CGH platform for hybridization and data
analysis.
"This Agilent certification will allow Quark to continue to
provide
dependable and high-quality microarray services," said Dr. Daniel
Zurr, Chief
Executive Officer of Quark Biotech, Inc. "Quark is very experienced
in the
microarray field and has been performing high volume microarray
experiments
based on its patented BiFAR(TM) platform for high-throughput
functional
profiling in the last six years."

About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is the world's premier
measurement
company and a technology leader in communications, electronics, life
sciences
and chemical analysis. The company's 28,000 employees serve
customers in more
than 110 countries. Agilent had net revenue of $7.2 billion in
fiscal year
2004. Information about Agilent is available on the Web at

www.agilent.com.

About Quark Biotech, Inc.
Quark Biotech, Inc. is a privately held development-stage,
biopharmaceutical company headquartered in Fremont, CA. Through
innovative
combination of gene silencing and DNA microarray technology, Quark
has
pioneered and patented its BiFAR(TM) platform for high-throughput
functional
profiling, allowing significant advances in the identification of
target genes
and proteins. This technology allows the company to develop
conceptually novel
drugs that provide previously unavailable benefits to patients.
Quark is
currently harvesting novel targets identified using this enabling
foundation
technology. Quark has focused development efforts on treatment of
fibrotic and
ischemic diseases of the eye, kidney and lungs, in indications with
clear
unmet medical needs.
Quark corporate product development teams and research
facilities are
based in Fremont, CA with research facilities also in Ness-Ziona,
Israel.
Additional information is available at www.quarkbiotech.com and at
www.quarklabs.com.

Arizona Biotech
Arizona Biotech
Entrepreneurs
Arizona SEO
Biotechnology News Forums
Biotech News
Biotech News

SMS.ac sms.ac sms.ac sms.ac
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] Hawaii Biotech's West Nile Vaccine Shows 100% Protection in Durability Study;

Hawaii Biotech's West Nile Vaccine Shows 100% Protection in
Durability Study; Third Study Confirms Vaccine Candidate's
Protective Efficacy

Hawaii Biotech, Inc., a privately held biopharmaceutical company
engaged in the research and development of human pharmaceuticals,
announced today that in a third study its West Nile vaccine
protected 100 percent of test animals from both illness and death
after six months when challenged with live West Nile Virus. In
contrast, 53.3 percent of the control animals died, and surviving
control animals all showed signs of illness. Two previous studies,
in which longer term durability was not assessed, also demonstrated
100 percent protection from both illness and death following live
West Nile Virus challenge. An additional study examining protection
at one year is underway.

The latest vaccine efficacy durability study was conducted in a well-
validated model of human West Nile disease, the golden hamster,
developed at the University of Texas Medical Branch. The study
consisted of three groups of fifteen animals each: one control group
and two groups immunized with Hawaii Biotech proprietary vaccine
formulations. Each group was vaccinated on day one, boosted on day
28 (controls were vaccinated and boosted with adjuvant only), and
then challenged six months post boost with a lethal dose of live
West Nile Virus. Morbidity and mortality were monitored for 30 days.
The results showed that all 30 animals that received Hawaii
Biotech's vaccine remained alive and healthy, with no signs of
illness at any time during the study. In contrast, all 15 control
animals, or animals that did not receive the vaccine became ill and
eight died with encephalitis.

The durability study was conducted by Dr. Douglas Watts, Professor
in the Department of Pathology, University of Texas Medical Branch
at Galveston, and complements two previous studies conducted at the
same university by Dr. Robert Tesh. "Vaccination is likely to be the
most effective measure against an infectious disease such as West
Nile," said Dr. Watts. "Hawaii Biotech's West Nile vaccine candidate
has demonstrated strong protective efficacy and good durability
extending out to at least six months."

Hawaii Biotech's genetically engineered, sub-unit vaccine technology
represents a potentially safer, non-infectious alternative to live
virus vaccines, which have an inherent risk of causing severe
disease in some people. Hawaii Biotech's proprietary sub-unit
vaccine, which combines a modern adjuvant with genetically
engineered viral proteins designed to eliminate the possibility of
viral disease, may confer a substantial safety advantage.

"We are very encouraged by the efficacy, durability and safety
profile of our West Nile vaccine candidate in these animal models,"
said David G. Watumull, President and CEO of Hawaii Biotech. "While
much work remains, these results support our goal of providing a non-
infectious vaccine that generates safe and effective protection
against West Nile Virus infection across all age groups.

About West Nile Virus

Virtually unknown in the U.S. prior to 1999, the West Nile virus is
now established throughout the U.S., Canada and Mexico (or North
America). Approximately 20 percent of those infected develop
systemic febrile illness, while about one out of 150 progress to
develop severe neurological symptoms. Approximately 5-14 percent of
the latter cases are fatal. Moreover, in a high percentage of the
non-fatal cases, permanent neurological disabilities result. These
clinical findings are significantly worse in elderly patients. The
CDC reported 2,539 cases and 100 deaths in 2004, with 1,141 (45
percent) of the 2,539 cases reporting neuroinvasive symptoms
(meningitis, encephalitis, or a poliomyelitis-like syndrome).

About Hawaii Biotech

Hawaii Biotech, Inc. is a privately held biopharmaceutical company
engaged in the research and development of human pharmaceuticals. It
is currently developing products from two broad product platforms:

-- Small molecules with potent anti-inflammatory activity but
without the side effects of steroids, aspirin, ibuprofen, Vioxx, and
Celebrex. First applications include: the reduction of peri-
procedural damage in angioplasty patients; and a treatment for
macular degeneration.

-- Targeted and rapid responses to emerging disease and
bioterrorism. First applications include safer, highly protective
vaccines for West Nile, dengue, and flu as well as small molecule
therapeutics for anthrax and dengue.

For more information, please visit www.hibiotech.com

Biotech News
Arizona Biotech
Entrepreneurs
Arizona SEO
Biotechnology News Forums
Biotech News
Biotech News

SMS.ac sms.ac sms.ac sms.ac
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] The Sixth European Biotechnology Symposium November 13 - 15, 2005; Competitive

The Sixth European Biotechnology Symposium November 13 - 15, 2005;
Competitive Biotechnology: Advanced Biologics Manufacturing and
Closing the Deal: Joint Ventures and Partnership

NEW ROCHELLE, N.Y.-- -- Aug. 9, 2005--Senior managers of
biopharmaceutical and pharmaceutical companies with responsibility
for biopharmaceutical product development, manufacture, regulatory
compliance and quality assurance, along with senior representatives
of companies providing services and support to biopharmaceutical
firms and major pharma will assemble at the Radisson SAS Scandinavia
Hotel in Copenhagen for the Sixth European Biotechnology Symposium.

Organized by BioConferences International, Inc., in cooperation with
GENETIC ENGINEERING NEWS, this symposium provides an opportunity to
gain a pan-European view of the industry and its business
environment and provides a forum for discussing biopharmaceutical
manufacturing for pharmaceutical and biotechnology companies in
Europe, from the USA, Canada and rest of the world, and fosters
opportunities for global marketing.

The opening plenary, Mammalian Cell Culture Processes for Large
Scale Operation from DNA to Product by Florian M. Wurm, PhD, Prof.
of Biotechnology, Swiss Federal Institute of Technology, Lausanne,
Switzerland, will help set the overall tone for the conference. Also
this year, with the addition of the Doing the Deal session, we will
have Gitte Pedersen, Special Advisor, Invest in Denmark introducing
the deal session with Linda Powers Managing Partner, Toucan Capital,
Bethesda, MD, Eric Halioua, Senior Manager, Arthur D. Little,
Boston, MA, Jesper Zeuthen, D.Sc. Managing Director, BanInvest
Group, Copenhagen, as well as Linda Horton, Regulatory Law Partner,
Hogan & Harrison, Washington, DC. The business perspectives provided
by these financial experts will complement the scientific and
technical presentations from the other speakers.

The conference offers many networking opportunities commencing with
an opening reception in the expo hall on Sunday evening, November
13, at the Radisson SAS Scandinavia Hotel, Copenhagen. Then Monday
and Tuesday continental breakfast, lunch and two networking
coffee/tea breaks will be in the expo area, giving delegates and
presenters an opportunity for networking prior to and in-between the
sessions. There is also a Monday evening Gala reception planned in
the Casino Ballroom. This offers an excellent backdrop for
networking, and collaborations for global marketing. There are
poster sessions in the expo hall as well. The meeting hall is right
next to the exhibit area and the posters, making everything very
accessible.

The Symposium, which begins Monday, November 14, uniquely addresses
biotech's two principal concerns, technology and business, through
two consecutive tracks. "Competitive Biotechnology: Advanced
Biologics Manufacturing" (morning and afternoon, November 14 and
morning of November 15) features leading European experts in
biomanufacturing.

Sponsors for the Sixth European Biotechnology Symposium include Host
Sponsor: Invest in Denmark, Chairs Cup: Pall Life Sciences,
Platinum: Sartorius, Diamond: Novozymes, Gold: Hyclone and Silver:
Stedim, CMC, Toucan Capital, Linde, Charles River, Cambrex,
Strathmann Biotec AG and BioKnex. Additional opportunities for
sponsorships and exhibitors and poster presenters are available.

Biotech
Biotech
Entrepreneurs
High Tech
Biotechnology News
Biotech News
Biotech News
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] The Biotechnology Association of Alabama Welcomes the Hudson-Alpha Institute for

The Biotechnology Association of Alabama Welcomes the Hudson-Alpha
Institute for Biotechnology


BIRMINGHAM, Ala., Aug. 9 -- The Biotechnology Association of
Alabama (BAA) extends its congratulations and welcomes the Hudson-
Alpha
Institute for Biotechnology to the City of Huntsville and the State
of
Alabama, following today's press conference announcing the creation
of a new
joint state and private supported research entity.
BAA Chairman, Matthew A. Gonda, Ph.D., and BAA Secretary, Greg
Peterson,
Ph.D., J.D., attended the news conference where Governor Bob Riley,
Dr. Jim
Hudson, founder of Research Genetics; Mr. Lonnie McMillan, co-
founder of
Adtran; and other Alabama notables officially announced plans to
create the
nonprofit research institute which will be built in Huntsville.
Industry
advocates see this as yet another sign that momentum is building as
the state
positions itself to expand its life sciences industry and promote
awareness of
existing business and research accomplishments.
"This new facility, with its focus on life sciences, will
substantially
impact Alabama by further elevating the state to showcase world
class research
in biotech and pharmaceutical research," says Dr. Gonda. "The
Biotechnology
Association of Alabama applauds Dr. Hudson, Mr. McMillan, the other
individual
contributors, Governor Riley and the state legislature for taking
this step
and showing their support. We in the industry applaud these efforts."
Dr. Peterson echoed those sentiments. "I cannot emphasize how
important
this announcement and the addition of this new research facility are
for
Alabama's high-tech future," says Dr. Peterson. "We see this as an
initiative
the state is taking to make life sciences a priority, and it is
further
evidence that the State of Alabama provides a good home for the
biotechnology
industry."
The Hudson-Alpha Institute announcement follows a host of other
encouraging events for the state during the past 18 months:
- The University of Alabama at Birmingham (UAB) topped $433
million in
externally funded research, 14 of its programs were ranked in
the top
25 nationally by U.S. News & World Report, and was named one
of four
institutions that will make up a new virtual Center for
HIV/AIDS
Vaccine Immunology (CHAVI) by the National Institute of
Allergy and
Infectious Diseases, part of the National Institutes of
Health seven-
year, $300 million award.
- Birmingham-based Southern Research Institute received FDA
approval of
clofarabine -- the sixth cancer drug discovered there -- and
was named
one of the nine Molecular Libraries Screening Centers being
funded in
the $88 million, three-year program funded by the National
Institutes
of Health as part of the NIH Roadmap Initiative to escalate
the
discovery and development of new drugs.
- Several biotech-related companies in Alabama, including
Transmolecular,
Inc., Tranzyme, Inc., and BioCryst Pharmaceuticals, Inc.,
raised
approximately $100 million in growth capital.
- Aetos Technologies, Inc. was founded as a financial
partnership with
Auburn University, its management team and private investors
to
commercialize and market technologies developed at Auburn as
well as
other academic and research institutions.
- The University of South Alabama in Mobile broke ground for the
University of South Alabama Cancer Research Institute, a
state-of-the-
art, 100,000-square-foot treatment and research center.
- The state saw the creation of eight new biotech-related
companies. More
than 90 biotech-related businesses now call Alabama home or
have major
operations here.
- Alabama enacted legislation creating the Certified Capital
Company
(CAPCO) program and allocated $100 million dollars of premium
tax
credits to insurance companies who match the states credit in
investment dollars to local venture capital firms to promote
investment
in Alabama-based businesses. The allocation of the tax
credits was made
in early February 2004 to six CAPCOs around the state
(www.ado.state.al.us).
- The Alabama Pavilion at the BIO 2005 International Conference
held in
Philadelphia last month was staffed by nearly 50 team members
and
received a significant increase in visitors to the Pavilion
and media
attention from the previous year.

About the Biotechnology Association of Alabama
The Biotechnology Association of Alabama was formed in 1997 by
biotechnology executives and community leaders to provide a unified
voice for
the state's emerging biotech industry. The BAA was incorporated as a
non-
profit trade association, 501(c)(6). The BAA sees great opportunity
in taking
advantage of Alabama's strong life sciences assets to build a future
that puts
the State in a leadership position in the nation and the world in
diagnosing,
treating and curing human and animal diseases while keeping our
environment
cleaner and safer. For more information visit www.bioalabama.com

SOURCE Biotechnology Association of Alabama
Web Site: www.bioalabama.com www.ado.state.al.us

Arizona Biotech
Biotech News
Arizona Entrepreneurs
Arizona High Tech
Biotechnology News Forums
Biotech News
Biotech News
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] Kreatech Biotechnology Launches PlatinumBright(TM) Nucleic Acid Labeling Kits fo

Kreatech Biotechnology Launches PlatinumBright(TM) Nucleic Acid
Labeling Kits for In Situ Hybridization and Filter Hybridization
Applications

Kreatech Biotechnology BV announces the launch of a series of
PlatinumBright nucleic acid labeling kits offering its' proprietary
ULS labeling molecule bound to a choice of fluorescent dyes or
haptens, The complete general nucleic acid labeling kits include
unique purification columns (KREApure) which ensure the complete
removal of unreacted dye while yielding very high sample recovery
that is independent of fragment length.

The Universal Linkage System - ULS(TM) - is a proprietary labeling
technology that has been engineered to give very reproducible
labeling densities, both inter- and intra-experimental protocols,
without the use of enzymes that can cause biases. While the labeling
in the PlatinumBright kits have been designed to provide the optimal
labeling density for Fluorescent in situ hybridization (FISH)
applications, the ULS labeling reaction in these kits are also
optimal for filter hybridizations such as Northern Blots, Southern
Blots, Spot Blots and Dot Blot hybridizations as well as use with
Tissue Arrays and ChIP on Chip experiments (labeling of promoter
fragments after Chromatin immuno precipitation).

ULS labeling of nucleic acids is a robust, one-step procedure that
is completed within 30 minutes. "The PlatinumBright nucleic acid
labeling kits offer the researcher the possibility to non
enzymatically label their target nucleic acid of choice, with a
choice of six commonly used dyes and a biotin kit and then proceed
to use this labeled material in several hybridization applications.
Our decision to make available the PlatinumBright general nucleic
acid labeling kits is consistent with our strategy to offer ULS
technology to researchers who have labeling needs for a variety of
nucleic acid applications. End users using PlatinumBright kits can
now very easily, quickly, and reproducibly label nucleic acids for
whatever application they can think of", according to Brent Keller,
General Manager/VP Commercial Operations for Kreatech.

Kreatech earlier this year launched a line of aRNA labeling kits for
expression arrays with dye pairs from GE Healthcare, Perkin Elmer,
Dyomics, and a Biotin system for Affymetrix users as well as a line
of arrayCGH labeling kits with the same dye pairs for the direct
labeling of genomic DNA for microarray based comparative genomic
hybridization analysis.

For more information on all of the ULS labeling kits visit
www.kreatech.com

Biotech
Biotech
Entrepreneurs
High Tech
Biotechnology News
Biotech News
Biotech News
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
Truth About Trade & Technology - Health Professionals Hold Positive Attitudes Toward Biotechnology
Truth About Trade & Technology - Health Professionals Hold Positive Attitudes Toward Biotechnology

Health Professionals Hold Positive Attitudes Toward Biotechnology



"Few biotechnology processes have elicited the degree of controversy that genetic manipulation of food through recombinant DNA technology has. Research has shown that consumers turn to health professionals for answers to questions regarding health and nutrition. This study sought to assess the knowledge, attitudes, and beliefs of physicians (MDs/DOs), nurse practitioners (NPs), and registered dietitians (RDs) toward food biotechnology and genetic engineering (GE)," investigators in the United States report.

"Six hundred three-part, self-administered surveys were sent to health professionals holding active professional licenses," said Jennifer Schmidt and colleagues at the Maryland Agricultural Education Foundation. "Statistical analysis included analysis of variance with Tukey's HSD and Scheffe's post hoc tests. Attitudes toward GE were positive. MDs held more positive attitudes than NPs or RDs (p=0.000). MDs and NPs supported the use of GE to improve plant resistance to pests; RDs tended to support nutritional-improvement technology."

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] Bolder BioTechnology Receives Funding From the National Cancer Institute to Eval

Bolder BioTechnology Receives Funding From the National Cancer
Institute to Evaluate Efficacy of a Second Generation Interferon
Gamma Protein for Treating Ovarian Cancer


WHEAT RIDGE, Colo., Aug. 12 -- Bolder BioTechnology, Inc.
today announced that it has been awarded a $121,844 Phase I Small
Business Innovation Research (SBIR) grant from the National Cancer
Institute of The National Institutes of Health. The grant provides
funds to evaluate effectiveness of the company's proprietary long
acting gamma interferon analog for the treatment of ovarian cancer
in animal models.

The SBIR program is a peer-reviewed grant program that provides
research support to small businesses to discover and develop
innovative biomedical products for the treatment of serious unmet
medical needs. Companies that successfully meet the goals of the
Phase I grant are eligible to apply for an additional $750,000 in
Phase II grant support to continue their product development efforts.

Bolder BioTechnology, Inc. uses advanced protein engineering
technologies to create proprietary, long-acting human protein
pharmaceuticals for the treatment of hematopoietic and endocrine
disorders, cancer and infectious diseases. For additional
information about Bolder BioTechnology, Inc., please visit our web
site at www.bolderbio.com.

Statements contained herein that are not historical facts are
forward-looking statements that are subject to a variety of risks and
uncertainties. There are a number of important factors that could
cause
actual results to differ materially from those expressed in any
forward-
looking statements made by the Company. These factors include, but
are not
limited to: (1) the Company's ability to successfully complete
product
research and development, including pre-clinical and clinical
studies, and
commercialization; (2) the Company's ability to obtain required
government
approvals; (3) the Company's ability to attract and/or maintain
manufacturing,
sales, distribution and marketing partners; and (4) the Company's
ability to
develop and commercialize its products before its competitors.

SOURCE Bolder BioTechnology, Inc.
Web Site: www.bolderbio.com

Biotech
Biotech
Entrepreneurs
High Tech
Biotechnology News
Biotech News
Biotech News
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
RedNova News - Health - Pennsylvania Biotech Firm to Open Office in Winston-Salem, N.C.
RedNova News - Health - Pennsylvania Biotech Firm to Open Office in Winston-Salem, N.C.

Pennsylvania Biotech Firm to Open Office in Winston-Salem, N.C.
Aug. 13--Tengion Inc., a Pennsylvania biotechnology company, said yesterday that it plans to open a satellite office in the West Point Business Park in Winston-Salem early next year, hoping to capitalize on research being performed at Wake Forest University.

The business plans to open a $9-million research and development laboratory and office at 3929 Westpoint Blvd., said Gary Sender, Tengion's chief financial officer. It will lease the space from Highwoods Properties, Inc, he said.

"It's been our intention all along to really be in the area," Sender said.

Tengion, based in King of Prussia, Pa., is a biotech company that develops cell tissues that can be used to create human organs. It is affiliated with Anthony Atala, a Wake Forest urologist who came to Wake Forest from Harvard University in the fall of 2003.

The company already licenses some of Atala's research. Tengion's local 20,000 square-foot office will primarily develop human bladders for organ transplants, company officials said.

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
Truth About Trade & Technology - My favorite Things Or What�s in the biotech pipeline?
Truth About Trade & Technology - My favorite Things Or What�s in the biotech pipeline?

My favorite Things Or What’s in the biotech pipeline?

by: Dean Kleckner, Chairman, Truth About Trade & Technology


Dean Kleckner


“If an elderly but distinguished scientist says that something is possible he is almost certainly right,” said author Arthur C. Clarke in 1969. “But if he says that it is impossible it is almost certainly wrong.”

When Clarke wrote those words a generation ago, how many people thought that in the early years of the 21st century farmers would routinely plant genetically-enhanced crops? The thought certainly never entered my mind. Perhaps one of Clarke’s fellow science-fiction novelists predicted it.

Whatever the case, what once seemed impossible isn’t merely possible--it’s downright routine. Nothing is more ordinary than biotech food these days. We eat it every day. Earlier this year, a farmer somewhere in the world planted humanity’s one billionth acre of biotech crops. In the coming weeks, that acre will be harvested.

Biotechnology has transformed our lives. The transformation will not only continue but the pace of change will actually quicken. Here are a few of my favorite potential developments, culled from newspaper clippings in recent months:

Weeds that detect land mines
The soybean club for men
Healthy tobacco
Plants vs. pollution
Medical milk
Vaccines

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
A $700M Biotech Park May Diversify NYC Economy
A $700M Biotech Park May Diversify NYC Economy

A $700M Biotech Park May Diversify NYC Economy
August 11, 2005
By Russ Colchamiro, Executive Editor


Commercial real estate analysts believe New York City might be in the early stages of a biotech boom, which could quite possibly change the landscape of the city's economy. The biggest boost thus far came from yesterday's announcement that REIT Alexandria Real Estate Equities Inc. will build a $700 million complex of commercial healthcare laboratories on the campus of the Bellevue Hospital Center.
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
Arizona Weblog Directory
Arizona Weblog Directory
Arizona News
Arizona Weblogs Directory
Phoenix Arizona
Arizona Weblog Directory

Arizona Weblogs Directory

Daily Bible Verse
Old Testament Bible Verse and New Testament Verse
Funny Jokes
Funny Jokes and Humor from a variety of sources.
Famous Quotes
The Original Famous Quotes And Famous Sayings Network Weblog.
Life Story Writing
Writing about Life
World Famous Recipes
Recipes and recipe sites are posted to this web log on an occasional basis.
Christmas Joy
Christmas Weblog - for Christmas all year round.
Search Engines
Search Engines - World Search News - Search Engine News.
Love Quotes
Love Poems | Love Quotes | Love Songs
Famous Quotes
Famous Quotes are submitted from many sources.
Arizona News
News from Arizona
Funny Quotes
A World of Funny Quotes - Quotes World posts quotations on a variety of topics.
Famous Quotes
Quotes from Famous People
Famous Cooking Recipe
All the right ingredients for your cooking and eating pleasure. Food and fun for everyone. Recipes for all occasions.
Jobs and Employment
Jobs and Employment Information and Sites.
Wireless LAN
Wireless LAN information and resources. News and opinions on wireless lan.
WLAN
Wireless LAN Forum
Writing Resources
Writing resources, writer news, and commentary for creative writing, writing poety, life story writing, fiction writing, non-fiction writing, freelance writing
Recipes on World Famous Recipes
If you are looking for recipes then you came to the right place.
Recipes
Cooks and chefs to find famous recipes and not so famous recipes for all occasions.
Arts and Entertainment

Quotes Exchange

Online Jewelry Stores

Jewelry Stores

Post Secrets

E-Commerce Solutions

Personal Finance

Stock Quotes

Famous People

Payday Loans

HTTP In Phoenix AZ

Books and Book Reviews

Phoenix Arizona

Arizona Biotech

Chicken Recipes

480 Area Code Guide

Bible Study Online

Progressive Arizona Network

SR22

Vending Machine News

Scottsdale Dentist

Phoenix Arizona Relocation

Health Wellness Fitness

Katheesuegee
I have no idea.
Daisy Dear
Daisy, Daisy, give me your answer Dear.
Stock Market Stock Trading Stock Quotes Stocks

Free Recipes Online

Funny Jokes

Diabetic Recipes

Garden Center

Free Recipes Online - Free Online Recipes

Search Engine Optimization


================================
Other Sites:

Phoenix Arizona Maricopa County Fair Famous Quotes Express Homebuyers Famous Quotes Gatlinburg Cabins Gatlinburg Cabins Vending Machines Vending Machines Fireplace Mantels Kitchen Hoods Fireplace Designs Custom Stone flow meter Garage Storage Cabinets SLIDE-Lok Dealer Chicken Recipes sms.ac sr22 DUI Famous Quotes Cleaning Products Famous Quotes Funny Quotes Payday Loans Maricopa County Fair Arizona State Fair Cooking Recipes Health Wellness Fitness Arizona State Fair Smoking and Staying Healthy Cash Advances Payday Loans Maricopa County Fair Chicken Recipes Recipes Bible Study Sexual Abuse Prevention Diabetic Recipes

Arizona Weblog Directory

Arizona Weblog Directory
Arizona Weblog Directory
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] Biotech Firm Spherics Relocating to Massachusetts and Building Manufacturing Fac

Biotech Firm Spherics Relocating to Massachusetts and Building
Manufacturing Facility, $2.5M Emerging Technology Fund Loan Clinches
the Deal

BOSTON Aug. 12, 2005 MassDevelopment, Spherics, Inc., the
Massachusetts Biotechnology Council (MBC), the Massachusetts Office
of Business Development, and the Massachusetts Alliance for Economic
Development today announced that Rhode Island-based Spherics will
relocate to Massachusetts. The company will move its headquarters
and research operations to Mansfield, as well as build a clinical
scale manufacturing facility.

In connection with the move, Spherics will receive a $2.5 million
loan from MassDevelopment's Emerging Technology Fund (ETF), the
largest ETF loan granted to date.

"Creating and fostering a business-friendly environment attracts
companies like Spherics," said Ranch C. Kimball, Governor Mitt
Romney's secretary of economic development and chair of
MassDevelopment. "Spherics' move is a tangible result of the
combined and coordinated efforts of the public and private sectors
to highlight the benefits of locating in Massachusetts."

Spherics is developing oral pharmaceutical products with improved
therapeutic profiles by applying its proprietary drug delivery
platform technologies. The Company's novel delivery technologies
improve drug performance by increasing absorption and residence time
in specific regions of the gastrointestinal tract. Spherics recently
raised $26.4 million in venture capital led by Advent International
of Boston to advance its clinical pipeline, which is principally in
the areas of central nervous system conditions, gastrointestinal
disorders, and cancer.

"This is a great win for Massachusetts," said Robert L. Culver,
MassDevelopment president/CEO. "Spherics is exactly the type of
company the legislature hoped to attract when it created the
Emerging Technology Fund. The firm's decision to relocate to
Massachusetts is a testament to the strength of our life sciences
community and the quality of our workforce in attracting companies
that are moving from research and development into manufacturing."

Capitalized by the state legislature last year, the Emerging
Technology Fund helps technology-based businesses locate and expand
in the Commonwealth. The fund targets companies that are ready to
transition from research and development to production. It provides
loans and loan guarantees for buying equipment, renovating leased
space or purchasing and expanding facilities.

The MBC and the state worked together to demonstrate the
Commonwealth's competitiveness. The Massachusetts team also worked
closely with Spherics and the town of Mansfield to identify a
suitable site for its new headquarters and manufacturing facility.

"Spherics' decision highlights the importance of the partnership
between state government and the biotechnology industry to sustain
Massachusetts' competitive advantage," said Thomas M. Finneran,
president of the Massachusetts Biotechnology Council. "Through our
collective efforts we have made great progress in attracting and
retaining biotechnology and pharmaceutical companies. It is
important that these efforts continue." He noted that Spherics is
the sixth biotech company to establish or expand manufacturing
operations in Massachusetts over the past two years.

"The move to Massachusetts will help accelerate our growth," said
Ze'ev Shaked, Ph.D., Spherics president/CEO. "The support we
received from the state and local officials, and from the
biotechnology community, were key factors in our decision."

The company has leased a 29,500 square foot facility in the Cabot
Industrial Park in Mansfield, MA, which will house its headquarters,
research and development, and manufacturing operations. The ETF
funds will be used to purchase new equipment and renovate the
facility. Spherics currently has approximately 25 employees, and is
expected to add up to 25 new jobs over the next three years.

Spherics is an emerging pharmaceutical company focused on applying
its proprietary oral drug delivery platform to develop products with
improved therapeutic profiles. The Company's novel delivery
technologies improve drug performance by increasing absorption and
residence time in specific regions of the gastrointestinal tract.
Spherics' business strategy is to further its proprietary pipeline
of drugs, while working with pharmaceutical companies in life-cycle
management and product line extension. For more information, visit
www.spherics.com.

The Massachusetts Biotechnology Council (MBC), founded in 1985, is a
non-profit organization that provides services and support for the
Massachusetts biotechnology industry. The MBC is committed to
advancing the development of critical new science, technology and
medicines that benefit people worldwide. Representing over 400
companies, academic institutions and service organizations involved
in biotechnology and healthcare, the MBC works with public leaders
to advance policy and promote education, while providing member
programs and services.

MassDevelopment, the state's finance and development authority,
partners with businesses and local officials to stimulate growth
across the Commonwealth. In fiscal year 2004, the agency arranged
financing for or managed 201 projects statewide totaling more than
$1.25 billion. These projects supported the creation of more than
5,500 jobs and 2,445 housing starts.

Arizona Biotech
Biotech News
Arizona Entrepreneurs
Arizona High Tech
Biotechnology News Forums
Biotech News
Biotech News

Funny Quotes - Famous Quotes - Love Quotes

Funny Quotes Famous Quotes Love Quotes

Funny Quotes Famous Quotes Love Quotes
Funny Quotes Famous Quotes Love Quotes
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
biotech slowdown?
A biotech slowdown? - The Boston Globe

biotech slowdown?
By Steven Syre, Globe Columnist | August 9, 2005

Listen closely, and you may be able to hear a little bit of air escaping from the biotech stock balloon.

Article Tools
Printer friendly
E-mail to a friend
Business RSS feed
Available RSS feeds
Most e-mailed
Reprints/permissions
More:
Business section |
Latest business news |
Globe front page |
Boston.com
Sign up for: Globe Headlines e-mail | Breaking News Alerts Biotechnology stocks have been on a tear over the last four months, but they eased back slightly over the past few trading days. It's tempting to see the most recent activity as a breather before biotech stocks resume their climb. It's more rational to view it as the early evidence of a stalling stock sector.

First, some background: Biotech shares stumbled through the first three months of 2005. Investors who had been upbeat on many biotech companies fell into a funk over product-safety issues. They were spooked by serious problems with Tysabri, the new multiple sclerosis drug developed by Biogen Idec Inc. and Elan Corp., not to mention Merck & Co.'s ongoing Vioxx disaster.




Arizona Biotech
Biotech News
Arizona Entrepreneurs
Arizona High Tech
Biotechnology News Forums
Biotech News
Biotech News

Funny Quotes - Famous Quotes - Love Quotes

Funny Quotes Famous Quotes Love Quotes

Funny Quotes Famous Quotes Love Quotes
Funny Quotes Famous Quotes Love Quotes
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
Biotechnology News at Arizona Biotech
Biotechnology News at Arizona Biotech
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] BIOTECHNOLOGY FOR HEALTH CARE


http://www.arizonabiotech.com/
<a href="http://www.arizonabiotech.com/">Arizona Biotech</a>
http://groups.yahoo.com/group/biotech-news/
<a href="http://groups.yahoo.com/group/biotech-news/">Biotech News</a>
http://www.arizonaentrepreneurs.com/
<a href="http://www.arizonaentrepreneurs.com/">Arizona Entrepreneurs</a>
http://www.azhttp.com/
<a href="http://www.azhttp.com/">Arizona High Tech</a>

	My Groups | biotech-news Main Page

---

YAHOO! GROUPS LINKS

•  Visit your group "biotech-news" on the web.
   
•  To unsubscribe from this group, send an email to:
   biotech-news-unsubscribe@yahoogroups.com
   
•  Your use of Yahoo! Groups is subject to the Yahoo! Terms of Service.

---

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] Generex Biotechnology Completes Acquisition of Custom-Made, Fully-Automated Equipment for Commercial Oral-lyn(TM) Production


http://www.arizonabiotech.com/
<a href="http://www.arizonabiotech.com/">Arizona Biotech</a>
http://groups.yahoo.com/group/biotech-news/
<a href="http://groups.yahoo.com/group/biotech-news/">Biotech News</a>
http://www.arizonaentrepreneurs.com/
<a href="http://www.arizonaentrepreneurs.com/">Arizona Entrepreneurs</a>
http://www.azhttp.com/
<a href="http://www.azhttp.com/">Arizona High Tech</a>

	My Groups | biotech-news Main Page

---

YAHOO! GROUPS LINKS

•  Visit your group "biotech-news" on the web.
   
•  To unsubscribe from this group, send an email to:
   biotech-news-unsubscribe@yahoogroups.com
   
•  Your use of Yahoo! Groups is subject to the Yahoo! Terms of Service.

---

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] Bringing Genomes to Life


http://www.arizonabiotech.com/
<a href="http://www.arizonabiotech.com/">Arizona Biotech</a>
http://groups.yahoo.com/group/biotech-news/
<a href="http://groups.yahoo.com/group/biotech-news/">Biotech News</a>
http://www.arizonaentrepreneurs.com/
<a href="http://www.arizonaentrepreneurs.com/">Arizona Entrepreneurs</a>
http://www.azhttp.com/
<a href="http://www.azhttp.com/">Arizona High Tech</a>

	My Groups | biotech-news Main Page

---

YAHOO! GROUPS LINKS

•  Visit your group "biotech-news" on the web.
   
•  To unsubscribe from this group, send an email to:
   biotech-news-unsubscribe@yahoogroups.com
   
•  Your use of Yahoo! Groups is subject to the Yahoo! Terms of Service.

---

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
Amgen, Biotechnology Stocks Rally on Earnings, Drugmakers' Woes
Bloomberg.com: U.S.

Amgen, Biotechnology Stocks Rally on Earnings, Drugmakers' Woes
Aug. 1 (Bloomberg) -- During Richard Drake's first five years as manager of the ABN Amro Growth Fund, he didn't own a biotechnology stock. That changed in March, when he bought Amgen Inc. and Gilead Sciences Inc. because he saw them as less-risky substitutes for bigger drug companies.

``Biotechs in the past have been one- or two-product companies, and were more volatile,'' said Drake, who oversees the $1.3 billion fund from Chicago. ``But we believe now the earnings stability is there.''

Shares of Amgen, Genentech Inc., Gilead and Genzyme Corp., the four largest biotechnology companies by market value, set records last month as second-quarter profit exceeded estimates.
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
Scientists Give Thought for Food at 2005 Biotechnology Conference
Scientists Give Thought for Food at 2005 Biotechnology Conference

Scientists Give Thought for Food at 2005 Biotechnology Conference
Writer: Janet Gregg, (972) 952-9232,j-gregg@tamu-edu
Contact: Dr. Rebecca Parker, (972) 952-9240,RHParker@ag.tamu.edu

DALLAS - Nobel prize winner Dr. Russell Hulse and Dr. Elsa Murano, vice chancellor and dean of agriculture and life sciences and director of the Texas Agricultural Experiment Station in the Texas A&M University System, were featured speakers at a recent biotechnology conference on food safety. The event was presented at the Texas A&M University System Research and Extension Center in Dallas.

Hulse opened the conference with a talk on "Science: From Nobel to Neighborhoods." He stressed the importance of instilling an excitement about science at an early age.

Hulse spoke on his road to the 1993 Nobel Prize in Physics. In 1974 he was a 23-year-old graduate student at the University of Massachusetts in Amherst, working on his thesis under the direction of Dr. Joseph Taylor Jr. Using a 1,000-foot radio telescope at the Arecibo Observatory in Puerto Rico, Hulse discovered the first binary pulsar.


Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] TGen and Northern Arizona University Awarded a Multi-million Dollar Grant to Identify Genetic Signatures of Pathogens


http://www.arizonabiotech.com/
<a href="http://www.arizonabiotech.com/">Arizona Biotech</a>
http://groups.yahoo.com/group/biotech-news/
<a href="http://groups.yahoo.com/group/biotech-news/">Biotech News</a>
http://www.arizonaentrepreneurs.com/
<a href="http://www.arizonaentrepreneurs.com/">Arizona Entrepreneurs</a>
http://www.azhttp.com/
<a href="http://www.azhttp.com/">Arizona High Tech</a>

•  Visit your group "biotech-news" on the web.
   
•  To unsubscribe from this group, send an email to:
   biotech-news-unsubscribe@yahoogroups.com
   
•  Your use of Yahoo! Groups is subject to the Yahoo! Terms of Service.

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
Arizona_biotech - Google Search
This is a very strange search. Can anyone searching for this tell me why?

Arizona_biotech

Arizona_biotech - Google Search




Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] BioTech Medics Announces Update From Bagell, Josephs & Co., LLC, CPAs

BioTech Medics Announces Update From Bagell, Josephs & Co., LLC,
CPAs


DALLAS, Aug. 4 -- Keith Houser, CEO of BioTech
Medics, Inc., (OTC Pink Sheets: BTMD) announced today that BTMD's
CPA firm of
Bagell, Josephs & Co., LLC has advised BTMD that they have completed
the 2002,
2003 & 2004 compilation of Corbel Holdings, Inc., financials.
Corbel was the
predecessor company to BioTech Medics, Inc. Corbel's Final 2004 IRS
Form 1120
as of December 7, 2004, (the date of the closing on the reverse
merger of BTMD
and Halolaser Biotherapy, LLC) indicates that Corbel Holdings, Inc.,
closed
its books with a $2,239,492 business loss.
Corbel Holdings, Inc. (formerly stock symbol: CBLH) was a real
estate and
property management holding company. Corbel owned property in
Tampa, Florida.
The disposition of the property took place in 2004 prior to the
December 7,
2004 reverse/merger.
"BTMD is negotiating for a business and medical office building
property
in Dallas," said Keith Houser. "We are seeking a property that can
provide
BTMD room for growth corporately and more space for our Dallas Pain
Management
& Wellness Center Clinic." We have narrowed our focus to a specific
property
that will provide a legal means for BTMD to incorporate the Corbel
2004
$2.239 million loss carry-forward advantageously. BTMD has made
application
for a commercial loan on the property, expects to have the terms
finalized
soon and a closing before the beginning of this fall.
BioTech Medics is the distributor for the NeuroLase Therapeutic
Medical
Device for the temporary reduction of muscular, skeletal and
arthritic pain.

Safe Harbor for Forward-Looking Statements
This press contains forward-looking statements within the
meaning of The
Private Securities Litigation Reform Act of 1995 (the "Act"). In
particular,
when used in the preceding discussion, the words "plan," "confident
that,"
"believe," "scheduled," "expect," or "intend to," and similar
conditional
expressions are intended to identify forward-looking statements
within the
meaning of the Act and are subject to the safe harbor created by the
Act.
Such statements are subject to certain risks and uncertainties and
actual
results could differ materially from those expressed in any of the
forward-
looking statements. Such risks and uncertainties include, but are
not limited
to, the ability of the company to have adequate financing, market
conditions,
the general acceptance of the Company's products and technologies,
competitive
factors, timing, and other risks described in various Company
publications.

SOURCE BioTech Medics, Inc.
Web Site: www.biotechmedics.com

Arizona Biotech
Biotech News
Arizona Entrepreneurs
Arizona High Tech
Biotechnology News Forums
Biotech News
Biotech News
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] NeoRx Joins The Scripps Research Institute in First Scientific Collaboration at Scripps Florida

NeoRx Joins The Scripps Research Institute in First Scientific Collaboration at Scripps Florida


-- Florida Governor Jeb Bush Lauds Research Agreement as First Major Biotech
Collaboration for Scripps Florida --

-- Focus to Be on Discovery of Novel, Small-Molecule, Multi-Targeted, Protein
Kinase Inhibitors for Cancer Treatment --

SEATTLE and PALM BEACH COUNTY, Fla., Aug. 4 NeoRx Corporation (Nasdaq: NERX), a cancer therapeutics development company,
and The Scripps Research Institute, a non-profit biomedical research
organization, today announced the first collaboration at Scripps Florida,
focusing on discovering novel, small-molecule, multi-targeted, protein kinase
inhibitors as therapeutic agents, including cancer treatments.
"The choice of NeoRx as Scripps Florida's first partner in biotech
research is truly exciting and is only the beginning of the many scientific
collaborations sure to come," said Governor Jeb Bush. "This partnership with
Scripps Florida will surely strengthen our state's position as a world leader
in curing disease and improving the human condition."
NeoRx is the first biotechnology company to enter into a research alliance
with Scripps Florida, the newly established division of Scripps Research in
Palm Beach County. NeoRx will provide $2.5 million over 26 months,
approximately $140,000 of which will be paid in 2005, to support the research
and will have the option to negotiate a worldwide exclusive license to any
compounds developed through the collaboration.
"We are excited to have selected NeoRx as our first biotech partner at
Scripps Florida and to move forward with this collaboration to identify
potential cancer treatments," said Richard A. Lerner, M.D., Scripps Research
president. "This is a significant opportunity, the first of many to come at
Scripps Florida, for collaboration between leading scientists to do
world-class science and discovery, ultimately leading to improvements in human
health."
"We are pleased to have entered into a research agreement with this
premier research institution and are hopeful that our collaboration will lead
to novel and unprecedented cancer products for our pipeline," said Jerry
McMahon, Ph.D., chairman and CEO of NeoRx. "While we are currently focusing
our resources on the clinical development of picoplatin, a next-generation
intravenous platinum compound, we are committed to broadening our cancer
portfolio to include agents with various mechanisms of action, including
targeted cancer therapies such as protein kinase inhibitors. It is becoming
clear that the use of both platinum-based chemotherapeutics and kinase
inhibitors either in combination or sequentially may provide important
clinical benefit to patients."
"Scripps Florida's selection of NeoRx as its first biotech partner
reflects NeoRx's experience and focus in oncology," said Thomas J. Pritzker,
chairman and co-founder of Bay City Capital and chairman and CEO of The
Pritzker Organization. "As a NeoRx investor, I am excited about the promise
of this research partnership."
The research collaboration will be led by Chris Liang, Ph.D., director of
medicinal chemistry at Scripps Florida. Dr. Liang's research focuses on the
discovery of novel pharmaceuticals for the treatment of cancer, arthritis and
asthma. He previously served as director of chemistry at SUGEN, Inc., a
biopharmaceutical company focused on the discovery and development of novel,
targeted small-molecule drugs. SUGEN, where Dr. McMahon previously served as
president, was acquired by Pharmacia in 1999, which subsequently was acquired
by Pfizer in 2003. While at SUGEN, Drs. Liang and McMahon were involved in
the discovery and development of SUTENT (SU11248), a novel, oral multi-
targeted tyrosine kinase inhibitor, currently in registrational trials with
Pfizer for the treatment of advanced cancers. Dr. Liang also developed a
novel computational model for predicting kinase selectivity of inhibitors by
analyzing the entire human kinase genome, or the kinome. In addition, he was
a key participant in the discovery of several additional drug candidates
currently in various stages of development by Pfizer.

About The Scripps Research Institute
The Scripps Research Institute in La Jolla, California, and Palm Beach
County, Florida, is one of the world's largest, independent, non-profit
biomedical research organizations. It stands at the forefront of basic
biomedical science that seeks to comprehend the most fundamental processes of
life. Scripps Research is internationally recognized for its research into
immunology, molecular and cellular biology, chemistry, neurosciences,
autoimmune, cardiovascular, and infectious diseases, and synthetic vaccine
development.
Scripps Florida, a 364,000 square-foot, state-of-the-art biomedical
research facility, will be built in the near future in Palm Beach County. The
facility will focus on basic biomedical science, drug discovery, and
technology development. Palm Beach County and the State of Florida have
provided start-up economic packages for development, building, staffing, and
equipping the campus. Scripps Florida now operates with approximately
100 scientists, technicians, and administrative staff at 40,000 square-foot
lab facilities on the Florida Atlantic University campus in Jupiter.

About NeoRx
NeoRx is a cancer therapeutics development company. The Company currently
is focusing its development efforts on picoplatin (NX 473), a next-generation
platinum therapy. A Phase II trial of picoplatin is currently under way for
patients with small cell lung cancer. The Company also plans to undertake a
Phase I/II trial of picoplatin in colorectal cancer in late 2005 or early
2006. As of June 30, 2005, the Company had cash and investment securities of
$11.5 million. For more information, visit www.neorx.com.
This release contains forward-looking statements relating to the parties'
research collaboration and product development efforts which are subject to
certain risks and uncertainties that could cause actual results to differ
materially from those projected. The words "believe," "expect," "intend",
"anticipate," variations of such words, and similar expressions identify
forward-looking statements, but their absence does not mean that the statement
is not forward-looking. These statements are not guarantees of future
performance and are subject to certain risks, uncertainties and assumptions
that are difficult to predict. Factors that could affect the parties'
research collaboration and product development efforts include the risks of
the uncertainties relating to the ability of the parties to successfully
discover, develop, test, secure regulatory approval of and finance any
compounds under the collaboration, the timing and amount of payments under the
arrangement, the sources and availability of additional financing of the
research and development of any product candidates, the parties' dependence on
patents and other proprietary rights; and, as to NeoRx Corporation, the risks
and uncertainties described in NeoRx's current and periodic reports filed with
the Securities and Exchange Commission, including NeoRx's Annual Report on
Form 10-K for the year ended December 31, 2004 and its latest Quarterly Report
on Form 10-Q. Readers are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date of this release.
The parties undertake no obligation to update any forward-looking statement to
reflect new information, events or circumstances after the date of this
release or to reflect the occurrence of unanticipated events.

SOURCE NeoRx Corporation
Web Site: www.neorx.com

Arizona Biotech
Biotech News
Arizona Entrepreneurs
Arizona High Tech
Biotechnology News Forums
Biotech News
Biotech News
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
Biotech's Growth Spurt Continues?
Biotech's Growth Spurt Continues?

Biotech's Growth Spurt Continues?
Despite the sector's rally, it may still have room to rise as S&P expects a strong slew of new product and supplemental approvals in 2006


In the run-up to this quarter's earnings reporting season, biotechs have been on a tear (the relative strength price chart for Standard & Poor's 1500 Biotechnology subindustry index is shown below). Year to date through July 15, the sector has surged 11.7%, compared to a 2.5% rise in the S&P Composite 1500 index. During 2004, this group gained 8.2%, vs. a 10% advance for the "1500."

Those are some impressive numbers, but such an advance can leave investors wondering if any upside potential is left for the group. Frank DiLorenzo, the S&P equity analyst who follows biotechs, thinks there may be some room to move higher. He recently raised his fundamental outlook on the biotech industry to positive, from neutral, based on S&P's expectations for a strong showing of new product and supplemental approvals in 2006.

AGGRESSIVE STANCE. DiLorenzo expects the flow of new products to provide a catalyst for the group and looks for industrywide share-price gains of about 20% over the next 12 months. Initial second-quarter results have been solid, in his view, and he expects this trend to continue for the second half of 2005.

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
Tax grab on patents damages biotech industry
National Business Review (NBR) - Business, News, Arts, Media, Share Market & More

Tax grab on patents damages biotech industry

Changes to tax policy meant to ease cash flow problems for technology firms selling patents fails to address a key issue raised by New Zealand’s biotechnology sector, according to NZBio CEO Brian Ward.

Since most patents do not result in commercially successful products, grabing a tax bite slows the transfer of intellectual property -- and cripples the industry.

“The value of biotechnology comes from a small number of very successful innovations. The legislation assumes that all technologies will result in successfully commercialised products, which is simply not realistic,” Mr Ward said.


Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
Nominations Being Accepted for 2005 Governor's Celebration of Innovation Awards
Nominations Being Accepted for 2005 Governor's Celebration of Innovation Awards

Celebrating those who emerge as the pacesetters for Arizona's rapidly growing technology industry; Nominations due by Friday, August 26, 2005

The Arizona Technology Council, High Technology Industry Cluster, Arizona Department of Commerce and the Southern Arizona Tech Council announce the call for nomination for this year's Governor's Celebration of Innovation Awards. The awards recognize the many contributions of professionals, companies and academia who, through technological innovation, show leadership in and passion for the state's technology community. The event delivers an insider look at emerging to established companies, carefully chosen by a selection panel to showcase innovation and growth potential.

Seven prestigious awards are available to those projects, businesses, organizations, educational programs, or individuals who exemplify outstanding achievements in technological innovation. Award recipients are selected by an independent judging committee, drawn from the fields of science, technology, venture capital and higher education.

"The Governor's Celebration of Innovation is a wonderful event and demonstrates the technology community in Arizona is growing rapidly. This event gives everyone a chance to pause and recognize all of the truly innovative local companies and their accomplishments. It was quite an honor to win an award last year considering the caliber of competition and previous winners. What made the evening even more special was that we were able to bring the whole company and our key advisors to celebrate with us. This Tech Council event really kicked off explosive growth for our company. The Innovator of the Year award is special to us since it does not honor just one invention, but rather KMI's team, vision and products as a whole," said Ed Koeneman, founder and COO, Kinetic Muscles Inc., Winner: 2004 Innovator of the Year -- Start-Up Company.

This year, presentation of the awards will take place on Tuesday, November 15, 2005, at an exciting dinner to be held at the Arizona Biltmore Resort & Spa.

To obtain nomination information, a list of past winners, and more about the awards and upcoming event, visit the official Governor's Celebration of Innovation Web site at www.celebration-of-innovation.com or contact the Arizona Technology Council office at 602-343-8324, ext. 104. Entries are due by August 26, 2005. There is a $35 fee per entry.

The following awards are open for entries until 5 p.m. on August 26, 2005.

-- William F. McWhortor Community Service Leader of the Year

Bestowed upon the individual who contributes to Arizona's technology industry through relentless community involvement, leadership and excellence in economic development activity. Any individual in industry, government or academia may be nominated. Award is limited to individuals residing in Arizona five years or more.

-- Ed Denison Business Leader of the Year

Presented to the individual who makes a positive contribution to Arizona's technology industry through sustained growth of their business or company. Any individual in a leadership position employed by an Arizona-based business, or division of a corporation operating in Arizona may be nominated for this award. Leadership qualities such as entrepreneurship, community involvement and management expertise will be considered. Award is limited to individuals residing in Arizona five years or more.

-- Pioneering Innovation

Presented to the company that has shown continued excellence in Arizona's technology industry through sustained business presence, corporate citizenship, community involvement and business success. A company of any size or technical discipline may be nominated. The award is limited to commercial enterprises doing business in Arizona for five years or more.

-- Innovator of the Year -- Start-Up Company

Presented to the company or licensed team that has achieved significant business success through innovation in the past calendar year and meets the following requirements: Must be actively selling or developing a commercially available product or service for less than 24 months; Must be deriving revenue and/or funding; Must demonstrate innovation and potential viability; Company must be based in Arizona; Innovation must be developed in Arizona; Must have a management structure of one or more persons; Profitability is not a requirement.

-- Innovator of the Year -- Small Company

Presented to the company or licensed team (no limit on the duration of the project) that has achieved significant business success in the past calendar year and meets the following requirements: Company must be in operation for 24 months or more; Company must be generating less than $50 million in annual revenue; Company must be based in Arizona; Innovation must be developed in Arizona.

-- Innovator of the Year -- Large Company

Presented to the company or licensed team (no limit on the duration of the project) that has achieved significant business success through innovation in the past calendar year and meets the following requirements: Company must be in operation for 24 months or more; Company must be generating $50 million or more in annual revenues; Company must be based in Arizona; Innovation must be developed in Arizona.

-- Innovator of the Year -- Academia

Presented to the department or office within an accredited higher education institution that has achieved success through innovation in the past calendar year and meets the following requirements: Has achieved success through research and development; Must demonstrate technical innovation, scientific achievement and potential commercial viability; Institution must be based in Arizona; Open to both students and faculty; Has contributed to economic development within Arizona through teaching, research or other academic pursuits.

About the Governor's Celebration of Innovation

The Governor's Celebration of Innovation was established in 2003 by combining two technology award ceremonies: the High Tech Industry Cluster's 17-year student awards ceremony and the Arizona Software and Internet Association's 10-year "Celebration of Innovation." With the addition of the Governor's support over the last two years, the Governor's Celebration of Innovation has become the premier technology community gathering of its kind in Arizona. The inaugural Governor's Celebration of Innovation took place in November 2003 and was a colossal success with more than 1,200 in attendance.

About the Arizona Technology Council

The Arizona Technology Council's vision is for Arizona to be recognized as a top-tier center for technology-based industries and businesses with an education system that produces a best-of-class 21st-century workforce in a statewide community where its citizens share in the highest quality of life possible. The Council's mission is to drive partnerships, policies and programs that advance the business climate for Arizona's technology community. The Council delivers on this mission by representing, supporting and advocating for member companies through initiatives, advocacy, networking and effective communications.

The Arizona Technology Council, a nonprofit membership-based technology association, currently represents more than 30,000 employees across more than 475 of the leading technology companies in industries including advanced manufacturing, aerospace, biotechnology, e-learning, environmental technology, software/Internet, semiconductor and telecommunications. The Council is led by its president, Todd Bankofier, chairman of the board, Paul Johnson, an appointed executive committee, and a board of directors comprised of a cross section of academic, private and public sector professionals. For more information visit http://www.aztechcouncil.org.

About the Southern Arizona Tech Council

The Southern Arizona Tech Council is a nonprofit organization formed in August 2000 whose mission is to promote and implement high-tech industry economic development and competitiveness in Tucson and southern Arizona. For more information visit www.satc-az.com.

About the Arizona Department of Commerce

Collaborating with economic development partners statewide, the Arizona Department of Commerce works to create jobs, expand the tax base, increase per capita income and promote a globally competitive business environment. The agency provides reliable information and research, community assistance, targeted business attraction and development coupled with strategic workforce development. Nationally and internationally, the Department of Commerce promotes Arizona assets: a growing, high-tech workforce; competitive operating environment; easy access to major markets; affordable, available real estate; reliable utilities; abundant natural resources and an unmatched quality of life. For more information visit www.azcommerce.com.

About the High Technology Industry Cluster

The High Technology Industry Cluster (HTIC) is dedicated to improving Arizona's ability to nurture its own high-technology companies through an ongoing program that addresses needs of technology industries. Our efforts are directed at assisting Arizona's high-technology companies become globally competitive. HTIC improves the business climate of the high-technology industry through: promotion; by championing changes in public policy, legislation, economic infrastructure, and education; through facilitation of university/business and business/business networking and partnering; and other key activities supporting technological innovation in Arizona.

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
Selangor Holds International Biotechnology Conference
Malaysian National News Agency :: BERNAMA

Selangor Holds International Biotechnology Conference


SHAH ALAM, July 4 (Bernama) -- About 300 participants from here and abroad are expected to attend the Bio Selangor 2005 conference to be held here next month which aims to put Selangor in the forefront of biotechnology development.

SSIC Bhd general manager, Datuk Mhd Jabar Ahmad Kembali said the conference, which is being organised by his company with the cooperation of Universiti Industri Selangor, would be held at the Concorde Hotel here from Aug 29-30.

"We want make Selangor a biotechnology hub in line with government's aim for it to be a major contributor to the economy," he told reporters, here Monday. SSIC is Selangor's investments promotion arm.


Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] BioTech Medics Announces NeuroLase Medical Device to be Featured

BioTech Medics Announces NeuroLase Medical Device to be Featured at
the 16th Annual American Academy of Pain Convention


DALLAS, Aug. 3 Keith Houser, CEO of BioTech
Medics, Inc., (OTC Pink Sheets: BTMD) announced today that BTMD in
cooperation
with Spectrum Laser & Technology of Colorado Springs will be
attending and
exhibiting the NeuroLase(TM) Therapeutic Medical Device at the 2005-
16th
Annual Clinical Meeting of the American Academy of Pain Management,
September
22-25, at the Manchester Grand Hyatt in San Diego, California.
The Academy anticipates up to 1,000 pain management clinicians
to attend
the meetings. The overall purpose of the Annual Clinical Meeting is
to
educate pain management clinicians and encourage open communication
among
them. Attendees will have an opportunity to learn about and
personally
experience the NeuroLase.
The American Academy of Pain Management is a nonprofit
organization
dedicated to serving a broad range of clinicians treating people
with pain.
Founded in 1988, the Academy now has approximately 6,000 members and
is the
largest interdisciplinary pain organization in the United States.
The NeuroLase is one of the most powerful USA - Class 3 B
Medical Lasers
cleared for the temporary reduction of muscle, skeletal or arthritic
pain over
the entire body.
"We are getting more calls from doctors around the USA desiring
information about the NeuroLase. Patients who have benefited from
being
treated for pain relief with the NeuroLase are getting the word out
as to the
safe, drug-free and surgery-free pain therapy," said Mr.
Houser. "With our
ability to offer 95% financing, the decision for a medical
practitioner to
acquire the laser becomes easier."

For More Information Contact BioTech Medics at 972-274-5533 or
on the
Internet at: www.biotechmedics.com

Safe Harbor for Forward-Looking Statements
This press contains forward-looking statements within the
meaning of The
Private Securities Litigation Reform Act of 1995 (the "Act"). In
Particular,
when used in the preceding discussion, the words "plan," "confident
that," "
believe," "scheduled," "expect," or "intend to," and similar
conditional
expressions are intended to identify forward-looking statements
within the
meaning of the Act and are subject to the safe harbor created by the
Act. Such
statements are subject to certain risks and uncertainties and actual
results
could differ materially from those expressed in any of the forward-
looking
statements. Such risks and uncertainties include, but are not
limited to, the
ability of the company to have adequate financing, market
conditions, the
general acceptance of the Company's products and technologies,
competitive
factors, timing, and other risks described in various Company
publications.

SOURCE BioTech Medics, Inc.
Web Site: www.biotechmedics.com

http://www.wireless--lan.com/
http://groups.yahoo.com/group/wirelesslan/
http://www.wlanforum.com/
http://chicken-recipes.blogspot.com/
http://quotations.home.att.net/funny.html

http://www.arizonabiotech.com/
<a href="http://www.arizonabiotech.com/">Arizona Biotech</a>
http://groups.yahoo.com/group/biotech-news/
<a href="http://groups.yahoo.com/group/biotech-news/">Biotech News</a>
http://www.arizonaentrepreneurs.com/
<a href="http://www.arizonaentrepreneurs.com/">Arizona Entrepreneurs</a>
http://www.azhttp.com/
<a href="http://www.azhttp.com/">Arizona High Tech</a>

Yahoo! Groups Links

<*> To visit your group on the web, go to:
http://groups.yahoo.com/group/biotech-news/

<*> To unsubscribe from this group, send an email to:
biotech-news-unsubscribe@yahoogroups.com

<*> Your use of Yahoo! Groups is subject to:
http://docs.yahoo.com/info/terms/

Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech

 
[ biotech news ] ARCH Venture Partners Names Steve Gillis, Co-Founder of Immunex and Corixa

ARCH Venture Partners Names Steve Gillis, Co-Founder of Immunex and
Corixa, as Venture Partner
Tuesday August 2, 12:56 pm ET

SEATTLE, Aug. 2 ARCH Venture Partners announced today that Dr.
Steven Gillis, Ph.D., co-founder of Immunex and Corixa Corporations,
has joined the firm as a Venture Partner based out of its Seattle
office.

Dr. Gillis will focus on assisting in the development and growth of
ARCH's biotechnology portfolio companies nationwide and will assume
Board roles in a number of those companies. He will also be active
in the evaluation of new life science technologies.

Dr. Gillis is a pioneer within the biotechnology industry and one of
its most respected executives, serving as Director of Research and
Development, Chief Scientific Officer, and eventually Chairman and
CEO of Immunex Corp., which he co-founded in 1981, and which was
acquired by Amgen in December 2001. Dr. Gillis also co-founded
Corixa Corp. in 1994 where he served as Chairman and CEO. Corixa was
acquired by GlaxoSmithKline in July 2005.

Robert Nelsen, Managing Director and co-founder of ARCH, said, "Dr.
Gillis will bring to ARCH extensive experience in creating and
managing biotech companies as well as rapidly developing products
from fundamental research. He is that rare combination of successful
entrepreneur and scientist, which fits well with ARCH's science-
driven approach to venture capital investment. We are delighted to
have someone of his caliber and experience join the ARCH team."

Dr. Gillis commented, "I look forward to helping ARCH and their
portfolio companies. I hope that lessons I have learned in the past
25 years in the industry will be of use, not only to existing
organizations, but to companies that may be put together in the next
several years."

An original recruit to the Fred Hutchinson Cancer Research Center in
Seattle, Dr. Gillis maintained an academic laboratory focused on
immune regulation. He received his B.A. from Williams College and
his Ph.D. from Dartmouth College.

About ARCH Venture Partners

ARCH Venture Partners focuses on creating early stage technology
companies in the life, physical and information sciences, which
emanate from universities, national laboratories and corporate
research labs. With over $1 billion under management, ARCH has
invested in the earliest rounds of more than 120 companies over a 20
year history. Early stage biotechnology investments include Caliper
Life Sciences, Adolor, Illumina, deCode Genetics, Aviron (acquired
by MedImmune), Array BioPharma, XenoPort, GenVec, Alnylam
Pharmaceuticals, Ikaria, NeurogesX, R2 Technology, and Trubion
Pharmaceuticals, among others. ARCH was also a seed investor in
companies such as New Era of Networks (acquired by Sybase), Nanosys,
Impinj, and MicroOptical Devices (acquired by Emcore).

www.archventure.com

Arizona Biotech
Biotech News
Arizona Entrepreneurs
Arizona High Tech
Biotechnology News Forums
Biotech News
Biotech News
Biotech News 0 comments

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech